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Abstract 
In the past years, genome biology had disclosed an ever-growing kind of 
biological targets that emerged as ideal points for therapeutic intervention. 
Nevertheless, the number of new chemical entities (NCEs) translated into 
effective therapies employed in the clinic, still not observed. Innovative strategies 
in drug discovery combined with different approaches to drug design should be 
searched for bridge this gap. In this context organic synthetic chemistry had to 
provide for effective strategies to achieve biologically active small molecules to 
consider not only as potentially drug candidates, but also as chemical tools to 
dissect biological systems. 
In this scenario, during my PhD, inspired by the Biology-oriented Synthesis 
(BIOS) approach, a small library of hybrid molecules endowed with privileged 
scaffolds, able to block cell cycle and to induce apoptosis and cell differentiation, 
merged with natural-like cores were synthesized. A synthetic platform which 
joined a Domino Knoevenagel-Diels Alder reaction with a Suzuki coupling was 
performed in order to reach the desired hybrid compounds. These molecules can 
represent either antitumor lead candidates, or valuable chemical tools to study 
molecular pathways in cancer cells. The biological profile expressed by some of 
these derivatives showed a well defined antiproliferative activity on leukemia Bcr-
Abl expressing K562 cell lines. 
A parallel project regarded the rational design and synthesis of minimally 
structured hERG blockers with the purpose of enhancing the SAR studies of a 
previously synthesized collection. A Target-Oriented Synthesis (TOS) approach 
was applied. Combining conventional and microwave heating, the desired final 
compounds were achieved in good yields and reaction rates. The preliminary 
biological results of the obtained compounds, showed a potent blocking activity. 
The obtained small set of hERG blockers, was able to gain more insight the 
minimal structural requirements for hERG liability, which is mandatory to 
investigate in order to reduce the risk of potential side effects of new drug 
candidates. 
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1.1 Drug Discovery: a brief history 
 
Over the past decades, there have been a significant advances in drug discovery 
approaches due to (i) the implementation of highly refined screening methods 
such as high-throughput or focused screening able to test rapidly synthetic and 
natural compound libraries; (ii) the improvement of synthetic strategies like 
combinatorial chemistry that offer the possibility to obtain great numbers of 
chemical compounds used to accelerate the drug discovery process.1 
Furthermore the genomic and proteomic approaches have disclosed promising 
new drug targets especially for cancer treatment.2-6 
Nevertheless in the same decades, an important decrease of the number of new 
chemical entities (NCEs) translated into effective therapies employed in the clinic, 
was dramatically observed. It’s well known that approximately 90% of drug 
candidates fail in the earlier phase of clinical trials.7 
What are the reasons of this decline in pharmaceutical research and 
development? Many hypothesis have been proposed and it has been highlighted 
that the increase in the rate of drug failing in clinical development was concurrent 
with the preeminence of the assumption that the drug discovery goal is to design 
very selective ligands able to interact with a single disease target. Ligands 
showing undesirable and potentially side effects have been reasonably removed. 
In other words the full realization of the “one drug, one disease” paradigm. 
Nowadays the emerged proof of multi-factorial pathogenesis of diseases such as 
neurodegenerative diseases and different type of cancer8 managed toward a 
different approach to drug design into discovery process.  
 
 
1.1.1 Paul Ehrlich’s Magic Bullet: Target-based Drug Design 
 
Paul Ehrlich, the founder of chemotherapy rewarded in 1908 with the Nobel 
Prize for Physiology or Medicine, is the father of the “magic bullet concept”, a 
postulate that inspired generation of scientists to device powerful products with 
ability to heal.9 
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1.1.2 Multiple ligand Approaches in Drug Discovery 
 
The parallel modulation of more than one biological targets could be promising 
approach for the treatment of diseases characterized by complex etiologies. 
The first effort in this direction, was fulfilled by polypharmacology, that 
combined different therapeutic mechanisms with “cocktail of drugs”. 
The benefit of this clinical practice resulted in improved efficacy and often 
reduced side effects in comparison with the single drug administration. 
Nonetheless this approach was often compromised by poor patient compliance 
especially regarding hypertension treatment.15 
In order to overcome this issue, an alternative strategy envisaged the use of a 
fixed dose combinations (FDCs), which implies the incorporation of two or more 
drugs into the same formulation.  
In this way a simplify dosing regimens and improving patient compliance was 
obtained but, at the same time, complications due to highly complex ADMET 
profiles and potential drug-drug interactions might make this path untenable. The 
third approach with a different risk-benefit relationship, was to develop “a single 
chemical entity able to modulate multiple biological targets simultaneously”.16 
Several clinically used drugs were known to hit more than one target, in some 
case this behavior was associated with increased efficacy, in other with side 
effects. The rational design of new chemical entities with specificity toward 
multiple targets involved in the same diseases, so called design multiple ligands 
(DMLs), represent a recent trend in drug discovery.17 
Beside the DMLs concept proposed by Morphy and Rankovic,16,17 according to 
Cavalli et al.,18 the definition “multi-target-directed ligands” (MTDLs) more 
completely describes the behavior of those compounds that are effective in 
treating multifactorial diseases due to their ability to interact with multiple 
targets18 (Figure 2). 
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Figure 2. MTDLs approach to drug discovery. (adapted from Cavalli et al.18). 
 
In this context, the design of multi-target-directed ligands (MTDLs) was achieved 
through two different methods: the first one by a screening approach and the 
second by a knowledge-based approach.16 
a. Screeening Approach 
In this method compound classes, known to be active towards one of the 
targets of interest, are focused screening against another one. Then the profile  
must be “balanced” during the optimization process in order to obtain the 
greatest affinity for all targets and at the same time “design out” additional 
undesired activities (Figure 3). 
 
 
Figure 3. Screening approaches (adapted from Morphy & Rankovic16). 
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b. Knowledge-Based Approach 
This second strategy, also called framework combination, offers the 
possibility to “design in” both different activities into a same molecule. 
Depending on the combination mode, the new ligands can be termed like: 
linked, merged or fused. In the first manner the frameworks are connected via 
a linker which in some case can be cleaved in vivo, to release the two distinct 
drugs. In the second mode the ligands are merged together and in the fused, 
the frameworks are directly attached (Figure 4). 
 
 
Figure 4. Knowledge-Based Approaches (adapted from Morphy & Rankovic16). 
 
 
1.1.3 Network Approaches 
 
In the last few decades drug discovery paradigm has shifted from ligand-
centric to target-centric approach.  
Although the advantages of starting from the knowledge of the target, this type of 
approach has been reassessed also in the light of the enormous advance in 
genomic field.  
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Indeed the post genomic-era has supplied huge omic-scale data for which it is 
necessary to adopt system approach in order to generate and makes sense of such 
data. Moreover this method afford to account as a part of whole system individual 
targets, studying its behavior inwards that whole.  
Networks, in term of linked graph, consist of nodes and edges in which the 
nodes represent individual molecular target, while the edges depict the 
interactions among them. In this way, the network approach entail a “brick-by-
brick” reconstruction of the system at a detail molecular level, then correlating the 
resulting outputs as a systems property.19-21 
Study of networks provide the basis to study important new areas such as: 
polypharmacology and combination targets, mechanism of drug action and drug 
safety, off-target effect and drug resistance.22 
 
 
Figure 5. Network models in Drug Discovery process (taken from Chandra et al.22). 
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1.1.4 Computational Approaches in Drug Design and Drug Discovery 
 
The fulfillment of human genome project unveiled the existence of 30-40,000 
genes and consequently, an equal number of proteins. Many of these proteins 
represent a potential targets, many of these targets could be “druggable”.  
In this contest the computational approaches in drug design represent an 
invaluable tools to span all stage of drug discovery pipeline: from target 
identification to lead discovery, up to lead optimization and preclinical or clinical 
trials23 (Figure 6). 
 
 
 
Figure 6. Computational approaches in Drug Discovery pipeline (adapted from Honglin 
et al.23). 
Drug design, sometimes referred to as rational drug design, is the ingenious 
process of finding new chemical entities based on the knowledge of a biological 
target24. New chemical entities may be designed to inhibit key molecules involved 
in a specific disease condition, or to enhance the normal signaling pathway taking 
advantage from well defined molecules that may be affected in the disease state. 
Furthermore new potential drugs should also be designed so as not to affect 
antitargets, that are responsible of undesirable side-effects. 
Drug design can be divided into two main types: ligand-based Drug Design 
and structure-based Drug Design. 
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Ligand-based Drug Design (or indirect drug design),25 starts from the knowledge 
of molecule able to bind to the biological target of interest. These molecules are 
used to describe a pharmacophoric model on which new chemical entities can be 
construct. On these basis a QSAR (Quantitative Structure-Activity Relationship) 
analysis, which correlate the molecular structural features with experimentally 
determined biological activity, can be performed. 
Struture-based Drug Design (or direct drug design),26 relies on the knowledge of 
3D structure of biological target, obtained by X-ray crystallography or NMR 
techniques, which is used to design new drug candidates. 
The main two computational techniques, ever-growing for drug design and 
optimization process27,28 are: virtual screening and focused combinatorial library 
design. 
 
a. Virtual Screening 
Virtual Screening performs a computational analysis on large-scale database 
of virtual libraries or chemical structures, for selecting a limited number of 
drug-candidates likely to be active against a specific biological target.29 
When the structure of the target is unknown, a pharmacophore model 
containing the key features, like hydrophilic or hydrophobic groups, is 
constructed by structure-activity relationship data of known 
pharmacologically active compounds. Such pharmacophoric features can be 
used as a template to select from the chemical database, the most promising 
candidates.  
When the structural informations of the target are available, e.g. by x-ray 
crystallography or homology modeling prediction, a molecular docking 
methods is used. Each molecule of chemical database is positioned into the 
binding site, the relative orientation and conformation are optimized and, at 
least, the molecules are scored for potential activity (Figure 7). 
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Figure 7. The flowchart for virtual screening (adapted from Honglin et al.23). 
 
b. Focused combinatorial libraries design. 
This approach includes: de novo drug design30 and combinatorial library 
design.31 
In the former, a complete molecule is built starting from a “building blocks” 
given the target binding site. The construction of the entire ligand usually 
occurs by linking molecular fragments (with either functional groups or 
small molecules), or by growing sequential-substituent on a “embryo”, 
taking into account the binding affinity. 
In the latter, the entire skeleton of a potential ligand is divided into several 
fragments on the basis of both interaction mechanism and physicochemical 
properties of the binding site. A fragment-library for each kind of fragment 
is constructed, according to the binding features. 
 
Nowadays computational approaches based on experimental data are constructed 
also for ADMET profiles prediction. As reported by Jorgensen27 reliable in silico 
models allow to predict several properties including partition coefficient 
octanol/water (logP),32 log BB (brain/blood partitioning),33 log Khsa for human 
16 
serum albumin binding 34 and log IC50 for HERG K+ channel blockage,35 other 
important end-point in drug development. It has been widely appreciated that 
ADMET profile should be involved in the early stage of drug discovery. 
 
 
1.1.5 Chemical Genetics-based Drug Discovery 
 
“Chemical genetics”36 is an emerging field which lies at the interface between 
synthetic organic chemistry and cell biology and it can be simply defined as a 
genetic study using chemical tools.36-39 
Its main goal is the exploitation of chemical compounds that may modulate 
biological systems, by a specific activation or inhibition of one or more target 
proteins,40,41 in order to explore, dissect and understand cellular pathways and 
biological function of proteins. 
The term Chemical Genetics highlights the similarity of this strategy to the 
classical genetic approach; in fact both study living system by perturbing specific 
pathways of interest, but in the former this is achieved by using small molecules, 
whereas in the latter by gene mutation.  
Genetics42 can be divided into Forward Genetics, which involves random 
mutation followed by phenotypic screening and subsequent gene identification 
and Reverse Genetics, that relies on mutation of a specific gene and phenotype 
characterization (Figure 8a). Remarkably, genetics in “forward” direction 
proceeds from phenotype to gene; in the “reverse” direction it advances from gene 
to phenotype. 
Chemical Genetics can be divided similarly.42 
In Forward Chemical Genetics the “mutations” are replaced by a screening of 
small molecule libraries against multiple potential targets simultaneously.40 
Suitable small molecule that induce the desired phenotypic effect can be selected 
and then the target protein that the compound is modulating must be identified. 
In Reverse Chemical Genetics a known protein target is screened using small 
molecule libraries in order to indentify functional ligands able to either stimulate 
17 
or inhibit the target protein. Once an appropriate binding partner is identified, it is 
introduced into a biological system (cell or organism) and the resulting effects 
induced in the phenotype are studied.40 
Thus, Chemical Genetics in “forward” direction is from phenotype to protein; 
in “reverse” proceeds from protein to phenotype41 (Figure 8b). 
 
 
Figure 8. a) Genetics approach b) Chemical-Genetics approach (taken fromStockwell42). 
Chemical genetics offers several advantages over its classical counterpart and 
afford to investigate unexplored biological space. 
The first advantage relies in a temporal control: all small molecules can be added 
or removed at any time, and their biological activities are usually rapid allowing 
instantaneous characterization of such effects. Moreover, in contrast to gene 
mutation, the effects induced by small molecules are often reversible, due to 
metabolism or cleaning, reaching protein function restoration.43 
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Also, a quantitative control is available; in fact small molecules effects are often 
tunable and therefore “dose-response” data can be produced by varying the 
concentration of the compounds. Lastly, small molecules can be used to study 
mammalian systems and several types of cells for which a classical genetic 
approaches is more challenging to apply.40 
The main disadvantage44 of a Chemical Genetics approach is that, at present, it 
cannot be applied generally. Indeed any gene in principle can be manipulated by 
genetics; but Chemical Genetics needs a small molecule ligand selective towards 
the protein of interest, and at this point in time only a tiny number of protein-
ligand partnership have been identified.  
The idea45 of using small molecules to dissect biochemical pathways is not 
new. There are many examples in which tracking down the phenotypic effects of 
small molecules has led to important biological discoveries; just thinking about 
the Hsp90 inhibitor Geldanamycin,46 or the Golgi disruptor Brefeldin A47 and a 
G2 checkpoint kinase inhibitor.48 Many small molecules were initially identified 
by their phenotypic effects, and the targets of these compounds were ultimately 
discovered providing important insights into their roles in various biological 
processes.  
Chemical Genetics concept, has been practiced for centuries also through the use 
of natural product compounds, and it may be considered a reinvention of classic 
pharmacology where, however, small molecule-protein interaction still remains a 
cornerstone. Given the macromolecule-perturbing role of small molecules, these 
are not only valuable tools to investigate pathway level and phenotypic profile, 
but they could also represent starting points for design and development of novel 
potential therapeutics.  
New insights coming from the systematic probing of biological pathways can then 
be used in drug discovery process to develop new pharmacological agents for 
promoting and restoring health (Figure 9). 
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Figure 9. Interconnections between Drug Discovery and Chemical Genetics. 
 
Indeed, starting from a disease-relevant cellular pathway, chemical genetics 
approach, exploiting small molecule tools, can disclose tractable targets within a 
molecular signaling pathway, explore the target’s function and understand its 
mechanism of action. Moreover, this method affords to assess both the biological 
activity and potential off-target effects of a drug candidate early in the drug 
discovery process, thus improving the entire process efficiency. 
Unlike the traditional target-based strategy that takes into account a predefined, 
often poorly validated target, the chemical genetics-based approach probes the 
entirely pathway for the most “druggable” node49 (Figure 10). 
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Figure 10. Conventional target-based drug discovery approach versus chemical genetics 
drug discovery approach (taken from Cong et al.49). 
 
In this scenario, small molecules have proven to be invaluable tools for 
investigating biological system. 
As reported by Schreiber50 the “central dogma” of life, according to which the 
information flows through macromolecules, from DNA to RNA to proteins, to be 
fully descriptive it should include small molecules. They are key elements in a 
range of topics at the heart of life sciences, such as the very origin of the life, 
memory and cognition environment, sensing and signaling field, treatment of 
disease.  
To this end Chemical Biology provides the missing piece of the central dogma 
which is represented by small molecules (Figure 11). 
A broad area of connection exists between the three family of macromolecules 
and small molecules, in both direction. Small molecules are synthesized to bind 
and modulate DNA, RNA or proteins functions and, at the same time, this 
macromolecules is used as a template to obtain small molecules. The principle “to 
understand a system, you need to perturb it”,51 underlies most of the experimental 
sciences and explain why our depth of understanding of biological systems has 
been widely determined by the availability of tools that can be able to disrupt it. 
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Figure 11. Central Dogma (as viewed by a chemical biologist).50 
 
 
1.2 Role of the Synthetic Organic Chemistry to gain access to biologically 
active small molecules. 
 
The remarkable ability of small molecules to exert powerful effects on the 
function of macromolecules essential for living systems, both as probes for 
understanding life process and as pharmacological agents for promoting and 
restoring health,52 makes crucial to gain access to these compounds using suitable 
synthetic organic tools. For this reason several efforts were applied in this 
direction, in order to reach effectively synthetic strategies able to explore both the 
biological and chemical space and to understand the relationship interconnected. 
Generally chemical or biological space is defined as a virtual n-dimensional space 
described by n descriptors which can be of chemical or biological nature and 
either measured or computed (Figure 12). 
Chemical space can be viewed “as being analogous to the cosmological universe 
in its vastness, with chemical compounds populating space instead of stars”.53 
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Figure 12. Chemical or biological space. 
 
Three main approaches are used by synthetic organic chemistry in order to reach 
small molecules and to investigate biological and chemical space:52 
 
Target-oriented Synthesis (TOS) 
Targeted Library Synthesis 
Diversity-oriented Synthesis (DOS) 
 
 
1.2.1 Target-oriented Synhtesis (TOS) 
 
Target-oriented Synthesis (TOS)52,54,55 approach has a long history in organic 
chemistry and relies on nature to discover small molecules endowed with 
attractive macromolecule-perturbing capability. The target structure for chemical 
synthesis can be selected from natural compounds, with known or supposed 
biological activity, which are isolated from extract mixture and properly 
characterized using appropriate spectroscopic methods.  
TOS relies on a systematic method to plan syntheses known as retrosynthetic 
analysis,52,55 a concept developed by Elias James Corey, that earned him the 
Nobel Prize in 1990. In his Nobel lecture, Corey56 explained: “target structure is 
subjected to a deconstruction process which corresponds to the reverse of a 
synthetic reaction, so as to convert that target structure to simpler precursor 
structures, without any assumptions with regard to starting materials. Each of the 
precursors so generated is then examined in the same way, and the process is 
repeated until simple or commercially available structures result
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1.2.4 Biology-oriented Synthesis
 
Another alternative approach to library co
Synthesis, term forged by Waldmann and 
conceptually alternative, but at the same time complementary approach to DOS 
concept. 
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for mapping either biologically relevant space or protein space to generate suitable 
hypotheses used for effectively
Two main methods are performed to achieve its goal: the Protein Structure 
Similariy Clustering (PSSC) and Structural Classification of Natural Product 
(SCONP). In PSSC the target proteins are classified into clusters 
structural similarity in their ligand
The SCONP method is a structural classification 
scaffold trees. It is able to map and correlate the molecule frameworks in a 
hierarchical manner (Figure 18)
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The PSSC may be used to select potential protein target while SCONP serves to 
identify new starting point for the design and synthesis of novel small molecule 
library. Biology-oriented Synthesis adopts structure-based hypothesis generating 
tools for mapping and explore relevant chemical and biological space in order to 
find new bioactive small molecules.67 
 
 
 
 
Figure 18. BIOS approach (taken from Kaiser et al.66). 
 
 
1.3 Small Molecules as Chemical Probes to the Study of Cancer Desease. 
 
Since part of my PhD work concerns identification of novel biologically active 
small molecules, which can be either antitumor lead candidates, or valuable 
chemical tools to dissect molecular pathways in cancer cells, I’ll give here a brief 
description of the main features involved in neoplastic disorders. 
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1.3.1 Cell cycle 
Cell cycle is the consecutive and ordered set of events that regulate eukaryotic 
cell’s growth and division. It consists of four distinct phases (Figure 19): the S 
phase, in which DNA replication occurs, and the M phase when mitosis and 
cytokinesis division occur; these phases are interchanged respectively with G1 
phase (preparation to replication) and G2 phase (interphase or preparation to 
mitosis). 
 
Figure 19. Cell Cycle 
In the G0 phase a cell exits from cell cycle, becoming quiescent and thus “resting” 
for long time (possibly indefinitely as in the case of neurons). Cell cycle 
progression is tightly coordinated between the different phases by a series of 
checkpoints that control if the cell enters correctly in the cycle, and prevent entry 
into the next phase until the events of the preceding phase have been completed. 
Several cell cycle checkpoints work in concert to ensure that incomplete or 
damaged chromosomes are not replicated. When a damage is found, cycle 
progression is stopped until repairs are made: if it’s possible to fix up, the process 
restarts, otherwise cells undergo through apoptosis. If a checkpoint stops working, 
mutations occur that can lead to cancerogenesis. 
 
1.3.2 Morphological features of apoptosis. 
 
The term apoptosis, coined by Currie, means “to fall away from” and it has 
been inspired from the release of apoptotic bodies that seems like the falling 
leaves from deciduous trees in the autumn.69 They represent one of the peculiar 
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morphological features by which apoptotic cells can be distinguished from 
necrotic cells. 
In apoptosis the cell shrinks, shows deformation and looses contact to its 
neighboring cells. Its chromatin condenses at once and moves to the nuclear 
membrane. Then, the plasma membrane is blabbing or budding, and finally the 
cell is fragmented into compact membrane-enclosed structures, called “apoptotic 
bodies” which contain cytosol, the condensed chromatin, and organelles70 (Figure 
20). Subsequently, the apoptotic bodies are swallowed up by macrophages and 
thus they are removed from the tissue without causing an inflammatory response. 
Conversely, in the necrotic mode of cell-death the cells suffer a major insult, 
resulting in a loss of membrane integrity, swelling and disruption. During 
necrosis, the cellular contents are released uncontrolled into the cell's environment 
damaging surrounding cells and causing a strong inflammatory response in the 
corresponding tissue.  
Many and different stimuli can trigger apoptosis, both from outside or inside the 
cell, they could be: activation factors of cell surface receptors, DNA damages,, 
exposure to cytotoxic drugs or irradiation, lack of survival signals and 
contradictory cell cycle signaling. 
 
 
 
Figure 20. Comparison of morphological features in apoptosis and necrosis. (taken from 
Gewies70). 
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1.3.3 Basic Apoptosis signaling pathway 
 
The most morphological changes that are recognized as apoptosis are caused 
by Caspases71-75 that, for this reason, can be considered the central executioners of 
apoptosis. 
Caspases constitute a highly conserved family of cysteine proteases, fourteen of 
which have been so far identified, which cleave their substrates at aspartic acid 
residues, usually at one or at most few positions in the primary substrate 
sequence. The term Caspases in fact means Cysteine-dependent aspartate-
specific proteases. 
Caspases, similarly to other proteases, are produced in cells as enzymatically 
inactive zymogens, named procaspases. These zymogens are composed of three 
domains: N-terminal prodomain which is removed during activation, a large 
subunit containing the cysteine residue (20KDa) and a small subunit (10KDa), 
sometimes separated by a linker peptide. In all the cases examined so far, the 
mature active form of caspases is a heterotetramer containing two p20/p10 
heterodimers each of which contributes aminoacids to the two active sites that 
appear to work independently. The N-terminal prodomain is often proteolytically 
removed, such as the linker peptide (Figure 21). 
 
 
 
Figure 21. A) Crystal structure of caspase-3 in complex with a tetrapeptide aldehyde 
inhibitor (red). B) Caspases are synthesized from inactive precursors by proteolytic 
cleavage. 
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Different mechanisms exist for activating initiator caspases: caspase cascade, 
induced proximity and association with a regulatory subunit. 
In the first one a proteolitic cleavage of procaspase leading to the active forms 
usually occurs right after Asp residues, suggesting the possibility of autocatalytic 
activation. This case concern caspase -3,-6, -7 activation. 
The induced proximity model is based on the empirical observation that the 
zymogen forms of unprocessed caspases are not entirely inactive but rather 
possess weak protease activity. When triggered by protein interactions, the 
zymogens cantrans-process each other, producing the fully active proteases. This 
is the case for caspase-8. 
The last one is the most complex activation mechanism and it is used for 
caspase-9. It entails a complex formation, named apoptosome, that represent the 
actual active form of the enzyme. The apoptosome is formed by the association of 
procaspase with other protein cofactors, Apaf-1 and cytochrome c, both released 
by mitochondria.  
 
 
1.3.4 Apoptosis and cancer. 
 
Once induced, cell death may occur through several pathways, some of which 
are well described while others still remain only partially understood. Apoptotic 
pathways can be subdivided into two main categories: the death-receptor 
pathways (or extrinsic pathways) and the mitochondrial pathways (or intrinsic 
pathways). The involvement of caspases as final executioners of cell death is a 
common feature of both mechanisms. 
As shown in Figure 22, the extrinsic pathway is triggered by ligand-induced 
activation of the death receptors at the plasma membrane, with subsequent 
activation of caspase-8. Conversely, the intrinsic cell death pathway is mediated 
by the activation of caspase-9 determined by cellular stress signals such as DNA 
damage. Caspase-8 and caspase-9 represent the initiator caspases that activate 
caspase-3 and caspase-7, the effector caspases. 
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Figure 22. Apoptotic pathways. 
 
When caspases become enzymatically active, apoptosis reaches the “point of 
no return”. For this reason it is necessary that this mechanism must be strictly 
controlled, and this control is achieved by numerous genes and proteins, 
categorized by their activities as inhibitors or initiators of apoptosis. In this 
endeavor, key regulators factors are represented by Bcl-2-family proteins that 
regulate caspase activation either negatively or positively. Given that, 
manipulation at the gene level of apoptosis such as shutting off anti-apoptotic 
gene expression or activating pro-apoptotic genes, as well as the use of small 
molecules to interfere with the apoptotic machinery at protein level, represent 
powerful potential strategies to develop new anticancer agents. For this purpose, 
Bcl-2 pro-apoptotic proteins have been extensively studied and have tremendous 
potential for clinical application.76 
Other apoptosis modulators activate cascades which are in turn subject to 
regulation by downstream factors such as Bcl-2.77 Among the upstream 
modulators are oncogenes such as c-myc, which activates apoptosis, but its 
function can be blocked by overexpression of Bcl-2 and so expansion of tumors 
can occur.  
Ultimately, tumor suppressor p53 induces apoptosis under certain conditions, 
thereby accounting for at least a portion of its tumor suppressive activity. 
Multiple novel strategies, focused on the key factors involved in cancer disease 
have emerged, nevertheless much remains to be learned among the complex 
cancer pathway. 
A distinct project fulfilled during my PhD study, regarded the design and 
synthesis of “minimally structured hERG blockers”, with the purpose of enhance 
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the SAR (Structure Activity Relationship) studies previously elaborated by us78 
and to gain more insight to drug-induced hERG blockade mechanism. Thus I’ll 
give here a brief description of the main features involved in this process 
 
 
1.4 Computational Approach Application to the study of hERG Blockage. 
 
Almost 10% of new chemical entities (NCEs) display serious adverse drug 
reactions (ADRs) after their introduction into medical practice and for this reason 
more than 17 drugs were withdrawn from the market during the period from 1996 
to 2006.79 As described by Graham80 and Schuster et al.:79 “the reasons for such 
ADRs, which are identified only after NCEs are launched on the market, include 
the narrow spectrum of clinical disorders and participating patient profiles in 
clinical studies as well as the fact that serious ADRs are often rare and that the 
number of patient exposures required to identify such occurrences sometimes may 
range over a few millions.” In this context it is mandatory to investigate all 
potential side effects of new drug candidate in the early phases of drug 
development in order to reduce the risk of drugs failure. 
In the past years, the design of new drug candidates aims to seek new 
compounds able to hit and bind specific target, while only recently the tendency 
emerged also to avoid some protein targets, due to their involvement in undesired 
effects. This issue is different from the simple search of selectivity, but considers 
some proteins able to bind a huge array of structurally different drugs, and whose 
binding by a drug provokes adverse and sometimes quite dangerous effects.81  
In this sense, the human ether-à-go-go-related gene (hERG) represents a typical 
and primary antitarget because its blockade is responsible for potentially fatal 
arrhythmias.82 
Currently, several methods for preclinical evaluation of hERG-related 
cardiotoxicity are available83 but some of these are often time-consuming and 
costly, so limiting their use in the early stage of drug discovery process. 
In this endeavor, the development of reliable theoretical methods able to predict 
hERG related cardiotoxicity is urgent. 
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1.4.2 From hERG blockade to QT prolongation. 
 
As described by Recanatini et al:84 “the QT interval is defined as the time 
interval between the onset of the QRS complex and the end of the T wave (Figure 
23) and therefore includes both the ventricular depolarization and repolarization 
intervals”.  
 
 
Figure 23. Illustrative example of QT interval (taken from Recanatini et al.84). 
 
Accordingly the QT interval reflects the lifetime of the action potential 
duration (APD) of cardiac myocytes, so APD prolongation will result in a 
prolonged QT interval. Cardiac action potential duration is controlled by a fine 
balance between the inward and outward currents during the plateau 
repolarization phase. 
The outward K+ currents, in particular the delayed rectifier repolarization current 
termed Ik, that represents the sum of two kinetically and pharmacologically 
distinct types of K+ currents: a rapid component Ikr and a slow one Iks. They play a 
crucial role both during plateau repolarization phase and in determining the 
configuration of APD. Small changes in conductance can significantly alter the 
effective refractory period, hence the action potential duration.82 
Although several pathophysiological mechanism can lead to QT prolongation,85-87 
the key mechanism for drug-induced prolongation of QT interval relies on the 
blockade of outward K+ currents (especially Ikr) which causes increased 
repolarization duration and consequently an increased cardiac action potential 
duration. In particular, most of the QT-prolonging drugs have been shown to 
inhibit the K+ channels encoded by the human ether-à-go-go-related gene 
(hERG)84 (Figure24). 
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Figure 24. Rapid component of the delayed rectifier K+ current (IKr) and slow component 
of the delayed rectifier K+ current (IKs) (taken from Recanatini et al.84). 
 
The great interest in QT prolongation is due to several reasons. The first reason is 
that QT prolongation increased the onset likelihood of torsade de pointes (TdP), a 
polymorphous ventricular arrhythmia which may cause syncope and degenerate 
into ventricular fibrillation and sudden death.88 
Second, it has been estimated that approximately 2–3% of all drug prescriptions, 
which comprise for example: antihistamines, fluoroquinolones, macrolides, and 
neuroleptics, involve medications that may unintentionally cause the long QT 
syndrome (LQTS).89 This explosion in the number of drugs prolonging the QT 
interval90 raises the question whether this is a class effects (e.g., shared by all 
agents of a given pharmacological class such as antihistamines) or a specific 
effect of a few agents within a pharmacological class. 
Third, QT prolongation and interaction with hERG K+channels have become 
surrogate markers of cardiotoxicity and have received increasing regulatory 
attention91 due to the fact that although potentially fatal arrhythmias associated 
with prolongation of the QT interval by non-cardiac drugs are difficult to occur 
during the I-III phase studies, because the relatively small number of subject 
involved, the LQTS is not an unusual findings and the correlated adverse 
reactions might be preventable. 
  
1.4.3 The hERG Potassium channel
 
The hERG channel 
family of voltage-gated 
family. Although the crystal structure of hERG channel is still not available, the 
basic 3D topology of its structure is quite similar to the other members of the 
voltage-gated K+ channel 
K+ channels are K+ ion selectivity proteins, 
and play a central role especially in the membrane electrical activity of ex
cells. Potassium channels carry out a basic function: the formation of a “leak” 
extremely specific for K
of K+ ions. As a consequence a negative
the membrane occur.
control of transcription and biochemical actions of the channel protein
of them are constitutively active while most of them act
signals control, such as in the case of K
hERG, like other Kv channels is a homo
transmembrane spanning 
S4 helices form the voltage
potential and is coupled to a central K
responsible for K+ conduction
 
Figure 25. Schematic rep
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Each pore domain consist of an outer helix (S5) and a inner helix (S6) that 
together coordinate the pore helix and selectivity filter (Figure 26). 
 
 
Figure 26. The four subunit of hERG Potassium channel (taken from Recanatini et al.84). 
 
The carboxy end of the pore helix and selectivity filter contain the highly 
conserved K+ channel signature sequence, which in hERG is Thr-Ser-Val-Gly-
Phe-Gly. This sequence form a narrow conduction pathway at the extracellular 
end of the pore in which K+ ions are coordinated by the backbone carbonyl 
oxygen atoms of the signature sequence residue.98 
hERG channel gating is distinctive in large part due to its unusual inactivation 
properties.99-101 Indeed, hERG shows an inactivation mechanism strongly voltage 
dependent and has much faster time dependent kinetics than activation gating, 
differently from most other voltage gated K+ (Kv) channel. As described by Perry, 
et al.98 hERG inactivation gating mechanism is not fully understood, but is likely 
to involve subtle conformational changes to the backbone of the selectivity 
filter102 that impair K+ ion coordination and block conduction. Furthermore hErg 
inactivation is sensitive to point mutations in the selectivity filter,100 pore helix103 
and outer mouth of the pore.104-106 
Extensive Ala-scanning mutagenesis of the hERG channel was performed to 
characterize the binding specificity of various drugs and drug-like molecules.93 
The mutagenesis data suggest that the most im
hERG binding include: Tyr652, Phe656 and Ile647 in the S6 helix, Ser620, Ser 
624, Ser631, and Val625 in the P
Among these, the two aromatic residues of the S6 helix: Phe656 and Tyr 652,
critical for all high-affinity blockers, while the two polar residues on the pore 
helix: Thr623 and Ser624 are important determinants for some, b
affinity drugs (Figure 27
 
Figure 27. Structure of the S5 and S6 subunits of hERG. (t
 
 
1.4.4 Computational Prediction of hERG Blockage
 
Several efforts have been enacted to predict 
this quantitative structure
modeling and homoly modeling wa
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comparing the topology of ring
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39 
portant residue involved in the 
-loop and Ala561 in the S5-P linker.
). 
 
aken from Wang 
 
hERG channel blockers, among 
-activity relationship (QSAR) studies, pharmacophore
s performed. 
 that few of known hERG blockers show ClogP < 1or 
-blockers. Furthermore, by 
-linker arrangements with the potential for 
 molecules with V-shaped geometry, stemming 
107 
 are 
ut not all, high-
et al.93). 
 
hERG 
40 
from ortho-substitution patterns show more possibility to be hERG blockers than 
the meta-/para-attached molecules, with linear topology.93 
Nevertheless, these simple rules are not reliable predictors of hERG blockers 
liability. It is necessary a more accurate prediction of hERG blockage and, for this 
reason, a broad range of quantitative structure activity relationship models was 
developed.109-114 
Considering the pharmacophore models for predicting hErg blockage, the first 
model was built by Etkins et al.115 and it derived from a training set of 15 
compounds characterized by ionizable center connected by four hydrophobic 
features. Then, other pharmacophore model was developed by Cavalli et al.,35 
Pearlstein et al.,116 Peukert et al.,117 Sanguinetti et al.,118 Matyus et al.,119 Du et 
al.,120 and Aronov et al..108,121,122 
All these published pharmacophore models show the following common features:  
(1) Two or three hydrophobic and/or aromatic moieties, which form 
hydrophobic and/or π-π stacking interactions with Tyr352 and Phe656 
in the S6 helix; 
(2) A protonated nitrogen, which is important to achieving high hERG 
potency but not necessary critical;121,123 
(3) Flexibility, which make a compound flexible when binding into the 
cavity.93 
Finally homology models were developed, using the crystal structures of Kcsa 
(closed), KvAP (open), and MthK (open).93 The homology models can be used for 
molecular docking, molecular dynamic (MD) simulations and free energy 
calculations to explore the hERG blockers interactions. 
All these computational approach could represent appropriate ways to overcome 
the challenges and could be helpful for designing drugs without undesirable 
hERG-ralated cardiotoxicity.   
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2. Aims of the Work and Synthesis 
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Given the powerful role of small molecules both as probes for understanding 
cell states and circuits, in dissecting systems biology, and in probing unknown 
side interactions, the new challenge of synthetic organic chemistry is to become 
the tool to gain access to collections of small molecules in highly efficient way. 
For this reason in the recent years there has been an increased interest toward 
innovative synthetic concepts or technologies.  
Among the latter, Microwave Assisted Organic Synthesis (MAOS) has become 
increasingly relevant both in medicinal chemistry and drug discovery pipeline.124 
MAOS replies to this challenge because it definitely reduces reactions time, 
typically from days or hours to minutes or seconds. Furthermore, MAOS allows to 
access to some transformations and reaction conditions which cannot be easily 
achieved under conventional heating.125 Finally, MAOS offers the possibility to 
perform chemical reactions in i) aqueous media, ii) using ionic liquids, iii) 
solvent-free conditions, making this synthetic application environmentally safe, 
according to the principles of green chemistry. 
 
 
2.1 Design and Synthesis of Bi- and Ter-Phenyl-Based Hybrid Molecules 
 
Over the past years, the research group in which I worked during my PhD has 
been engaged in a project aimed to identify novel biologically active small 
molecules, which can be either antitumor lead candidates, or valuable chemical 
tools to study molecular pathways in cancer cells. In this context the peculiar 
biological effects showed by some derivatives belonging to a small library of bi-
and-terphenyls126,127 prompted us to continue the study of this class of 
compounds. Therefore in order to increase the structural complexity and diversity 
of the existing collection, a library of new molecules, that are hybrids of 
spirocyclic ketones with biphenyls and terphenyls, was synthesized.128,129 The 
new compounds exhibited a natural product like scaffolds both as complexity 
bearing core and as biologically validated starting points (BIOS moieties),130 
combined with biphenyl and terphenyl as privileged fragments131-135 (Figure 28). 
Noteworthy a class of natural terphenyl derivatives with the spiro ring motif 
(spiromentins) is also present in nature.136  
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Figure 28. Library of hybrids of spirocyclic ketones with biphenyls and terphenyls. 
 
Some of the newly-shaped compounds showed a well-defined activity on 
apoptosis or differentiation in leukemia cells. In particular the compounds 1, 2, 3 
and 4 (Table 1) were clearly different with respect to the previously studied 
terphenyls that showed mixed pro-apoptotic and differentiating actions.129  
 
Table 1. IC50a (µM ± SE) and AC50b (µM ± SE) of derivatives 1-4 in Sensitive HL60 and 
Bcr-Abl-expressing K562 Cells. 
Compounds 
HL60 K562 HL60 K562 
IC50a IC50a AC50b AC50b 
 
1 
6±1 8±1 11±2 25±3 
 
2 
8±1 9±1 16±1 33±5 
 
3 
6±1 14±2 12±2 80±9 
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4 
16±2 8±1 32±4 >100 
aConcentration (µM) able to inhibit 50% of cell growth after 48 hours of treatment; 
bConcentration (µM) able to induce apoptosis in 50% of cells calculated after 48 hours 
of treatment. 
 
Moreover, in agreement with their marked pro-apoptotic activity in Bcr-Abl-
expressing K562 cells, 1 and 2 decrease the expression levels of Bcl-2 that play a 
main role in Bcr-Abl dependent apoptotic resistance. In contrast 3 an 4 according 
to their marginal ability to induce apoptosis in K562 cells did not cause any 
significant modification of Bcl-2 levels (Figure 29). 
 
Figure 29. Effects of compounds1, 2, 3 and 4 (30 µM) on Bcl-2 expression in K562 
cells after 24 hours. 
 
Finally compounds 3 and 4 were able to induce morphological and functional 
differentiation in HL60 cells129 (Figure 30). 
 
Figure 30. Morphologic changes observed in HL60 cells (promyelocytic acu
after 96 h exposure to 
after treatment with 4; 
from HL60 exposed 96 h to 
 
To study more in depth 
protein expression profiles of K562 cells treated with or without the compounds 
2, 3 and 4, were analyzed using two dimensional gel electrophoresis coupled with 
mass spectrometry. 
expressed proteins, mainly related to cellular metabolism, chaperone activity, 
cytoskeletal organization and RNA 
relevant relationships between the identified proteins and additional potential 
effectors. Notably, compound 
factors EGR1 and consistently with this it was able to induce megakaryocytic 
differentiation in K562 
A                             B                          
Figure 31. Morphological changes observed in K562 cells after 72
of 4. (A) Control; (B, C
megakaryocytic morphological aspects.
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cells137 (Figure 31). 
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On the basis of these interesting results, my thesis work was focused on the 
follow-up studies, making systematic structural modifications of the identified 1-4 
hits. 
Initially, different substituents on the bi- and- terphenyl fragments were 
introduced (Figure 32 A). Secondly, the spirocyclic portion was modified 
obtaining substituted cis-2,4-dimethyl-2,4-diazaspiro[5,5]undecane-1,3,5,9-
tetraone (Figure 32 B). Finally to enhance the structural complexity and diversity 
of the existing collection, some polycyclic ring bearing bi-and-terphenyl 
fragments were synthesized (Figure 32 C). 
 
 
 
Figure 32. New spirociclic and polyciclic derivatives. 
 
From a chemical point of view, all these scaffolds are particularly suitable to 
the rapid parallel synthesis. Indeed the new library of spirociclic ketons was 
prepared through parallel solution phase synthesis as previously reported taking 
advantage from a Domino Knoevenagel/Diels-Alder sequence coupled to a 
Suzuki reaction, carried out in a Carousel reaction station.128,129 
An analogous synthetic platform was performed for the construction of polycyclic 
derivatives. 
In particular spirocyclic central cores were synthesized using Domino 
Knoevenagel/Diels-Alder epimerization reaction as reported by Pizzirani et 
al.128,129 In this synthetic route the suitable commercial active methylene 
compounds 5a-c, were allowed to react with the appropriate aldehydes 6a 
(commercially available) and 6b-c,138 in the presence of a catalytic amount of (L)-
5,5-dimethyl thiazolidium-carboxylate (L-DMTC) to give the corresponding 
Knoevenagel adducts 7a-e in almost quantitative yield. These intermediates 
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represented the dienophiles in the subsequent Diels/Alder reaction. Accordingly, 
7a-e efficiently underwent concerted [4+2]-cycloaddition reaction with 2-amino-
1,3-butadiene 8, generated in situ from the commercial (E)-4-phenyl-3-buten-2-
one 9 and (L-DMTC).  
The Domino sequence proceeded in good yields and in highly diasterospecific 
way, providing the termodinamically more stable cis-spirane 10a-e (Scheme 1) as 
a major diasteroisomer due to the catalyst induced epimerization of the minor 
trans isomer, occurring under the same conditions with an extended reaction time. 
The cis-steorechemistry of the products was established by NOESY analysis (data 
not shown). 
 
SCHEME 1a 
 
 
 
aReagents and conditions: MeOH, r.t., 72 h. 
 
The obtained core structures 10a-e, bearing aryl bromide functionality which 
allowed the introduction of the desired biasing elements, are shown in Chart 1. 
  
R
O
O O
Ph
O
Me
S
N
H
Me
CO2H
Me
O
O
H
R
S
N
Me
CO2H
Me
Ph
O
Ph
O
O
R
6a-c
5a-c
9 7a-e 8 10a-e
48 
CHART 1. Domino Knoevenagel/Diels-Alder/epimerization reaction (K-DA-E). 
Entry 5 6:R 7 Enone Product 
1 
 
 
 
 
5a 
6a: R=Br 7a 9 
 
10a 
2 
 
 
 
 
5b 
6a: R=Br 7b 9 
 
10b 
3 
 
5c 
6a: R=Br 7d 9 
 
10c 
4 5b 6b: R= 3-BrC6H4 7c 9 
 
10d 
5 5c 6c: R= 4-BrC6H4 7e 9 
 
10e 
O
O
O
O
O
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N
N
CH3
CH3
O
O
O
O
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As described above the compounds 10a-e included an aryl bromide 
functionality which was essential for the derivatization step. Thus to introduce 
biphenyl and terphenyl moieties on these natural product-like scaffolds, a Suzuki 
coupling reaction was performed. In this synthetic route, run in parallel, the aryl 
halide 10a-e were coupled with appropriate boronic acids 11a-h via palladium-
catalyzed coupling reaction, using tetrakis (triphenylphosphine)-palladium(0) 
(Pd(PPh3)4) as catalyst, toluene/ethanol as solvents, and aqueous Na2CO3 to 
provide the basic environment required. The reactions were completed in 3-5 
hours to afford the desired compounds 12a-m in moderate to good yields 
(Scheme 2). 
 
SCHEME 2a 
 
 
 
aReagents and conditions: Pd(PPh3)4, Na2CO3 2M, Toluene/Ethanol 3:1, reflux, 3-5 h. 
 
The obtained final bi- and ter-phenyl derivatives 12a-e, bearing the biasing 
elements, are shown in Chart 2. 
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CHART 2. Suzuki coupling K-DA-E products 10a-e with various arylboronic acids 11h. 
Entry 10 11 Product 
1 
 
 
 
10a 
 
 
 
 
11a  
12a 
2 10a  
 
11b 
 
 
12b 
 
3 
 
 
 
10b 
11a 
 
12c 
4 10b 11b 
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O
O
O
O
O
OMe
MeO
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5 10b 
 
 
11c 
 
12e 
6 
 
10c 
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12f 
7 10c 
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12g 
8 
 
10b 
 
11f 
 
12h 
N
N
CH3
CH3
O
O
OH
O
O
O
O
O
O
O
OMe
MeO
OMe
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10d 
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10 10d 
 
11h 
 
12l 
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For the construction of the polycyclic core, a different type of Domino 
Knoevanagel Hetero Diels-Alder reaction was performed. This synthetic route 
firstly described by Tietze139 was carried out as a “two component” reaction, 
putting together a 1,3-dicarbonyl compound and an aldehyde containing a 
dienophile moiety. A cycloaddition took place in intermolecular fashion. 
O
O
O
O
O
Br
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The functionalized aldehyde 13,140 bearing a double bond in the side chain, 
underwent a Knoevenagel reaction with the highly reactive 1,3-dimethylbarbituric 
acid 5c using EDDA (ethylenediammonium diacetate) as a mild catalyst, to reach 
the intermediate 14 that couldn’t be isolated. This benzylidene intermediate 14 
contained either a diene and a dienophile moiety, thus the subsequently hetero 
Diels-Alder cycloaddition occurred via intramolecular mechanism. The 
transformation was extremely stereoselective, giving exclusively the cis-fused 
tetracycle 15139 (Scheme 3, route a). 
The cis-steorechemistry of the product was established by NOESY analysis (data 
not shown). The same reaction was performed under microwave irradiation with 
the aim to explore the possibility to further enhance the yield and reaction rate. 
On the basis of the synthetic procedures built up by Kappe et al. both for 
Knoevenagel141 and Diels Alder142 reactions, we have thought to combine the two 
methodologies, setting up a synthetic platform that proceeded through two 
consecutive reaction steps: the former to produce the Knoevenagel adduct 14 and 
the latter to obtain the desired cicloadduct 15 (Scheme 3, route b). 
 
SCHEME 3a 
 
 
 
aReagents and conditions:a) Aldehyde (1.5 equiv), 1,3-dimethylbarbituric acid (1 
equiv), CH2Cl2, r.t. 5h; b) Aldehyde (1 equiv),1,3-dimethylbarbituric acid (1.5 equiv), 
EtOH step 1: 140° C, 100 W, 10 min.; step 2: 160° C, 100 W, 5 min. 
 
The polycyclic compound 15, was appropriately functionalized with a bromine 
to sustain Suzuki coupling reactions by means of by- and ter-phenyl derivatives 
were achieved. Firstly, the compound 15 was allowed to react with boronic acid 
11d using the same Suzuki coupling conditions reported above for the spiro-
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derivatives. The desired biphenyl compound 16a was obtained with low yield 
(24%) (Scheme 4, route a), hence in order to improve the amount of the final 
product, MAOS was applied using tetrakis (triphenylphosphine)-palladium(0), 
Na2CO3 aqueous solution and the solvents pair Ethanol/Water.142,143 The product 
16a was collected with an incremented yield up to 80% and reaction rate of 10 
minutes (Scheme 4, route b). 
Afterwards, to prove the reliability of this microwave method, the same 
conditions were adopted for the reaction between 15 and the boronic acid 11e, 
recovering the desired 16b with a yield of 90% (Scheme 4, route b). 
 
SCHEME 4a 
 
 
 
aReagents and conditions:a) Pd(PPh3)4, Na2CO3 2M, Toluene/Ethanol 3:1, reflux, 3-5 h.; 
b) Na2CO3 2M, Pd(PPh3)4, EtOH/H2O 2:1, 150° C, 40 W, 10 min. 
 
To obtain the terphenyl derivative 16c a Miyaura Borylation-Suzuki Coupling 
under microwave irradiation, was explored.144 
In 1995 Miyaura and coworkers145 found that bis(pinacolato) diboron could be 
coupled with aromatic halide in the presence of catalytic amount of [1,1'-
Bis(diphenylphosphino) ferrocene]dichloropalladium (Pd(dppf)Cl2) to afford 
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arylboronic esters, useful substrates for Suzuki reactions.146 Thus treating the 
biaryl 17147 with commercial bis(pinacolato)diboron 18 in the presence of KOAc 
2M, and Pd(dppf)Cl2, under microwave irradiation, the arylboronic ester 19 was 
obtained in good yield. Finally, 19 was subjected to a Suzuki reaction with the 
polycyclic compound 15, using PdCl2(dppf)CH2Cl2 as a catalyst and Na2CO3 2M 
as a base, to achieve the desired terphenyl compound 16c (Scheme 5). 
 
SCHEME5a 
 
 
 
aReagents and conditions: a) KOAc 2M, PdCl2(dppf), DME, 150° C, 250 W, 20 min; b) 
Na2CO3 2M, PdCl2(dppf)CH2Cl2, DMF, 120° C, 150W, 10 min  
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The overall superimposition of compounds set led to a pharmacophoric model 
consisting of: (i) two aromatic rings (C0 and C1) almost coplanar and at a distance 
of approximately 4.5-6.5 Å, (ii) one basic nitrogen atom (N) approximately 5-9 
and 5.5-7 Å far away from the ring C0 and C1, and (iii) a further aromatic moiety 
(C2) required for increasing potency against hERG, which is approximately4.5-
7.5 Å from the nitrogen atom78 (Figure 34). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a                                 b 
 
Figure 34. (a) View of the superimposition of compounds set from which the 
pharmacophore was obtained (taken from Cavalli et al.35 (b) Pharmacophore model of 
hERG K+ channel blockers.78 
 
Furthermore a 3D QSAR model for predicting hERG binding potency of novel 
drug candidates,35 obtained through the CoMFA (Comparative Molecular Field 
Analysis)148 technique, that attempts to correlate the physicochemical features of 
the drug molecules with their blocking activity toward the hERG K+ channel, was 
developed. As described by Cavalli et al.,35 the CoMFA model reported in Figure 
35 “showed that sterically favorable regions (green) are located around the 
pharmacophoric points C1 and mostly C2, while the space around C0 seems 
sensitive to both steric and electrostatic properties of the molecules. Particularly, 
the yellow contour indicates that increasing bulk is detrimental for the activity, 
while the red and blue contours (which are not, as it might appear, on the same 
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line but show the blue volume pointing outward with respect to the red ones) 
indicate a prevalent favorable effect of positively and negatively charged groups, 
respectively”. 
 
 
 
Figure 35. Steric and electrostatic CoMFA contour maps.78 
 
On the basis of these computational study, we synthesized a small set of 
molecules 20-25 (Table 2) endowed with the minimally structured requirements 
to bind and block hERG K+ channel.78 Moreover in order to evaluate the role of a 
positive charge on hERG block potency, a further two compounds were obtained 
(26 and 27) in which a methylenamine was substituted with a methanamide 
group.78 The capability of hERG K+ current inhibition of 20-27 was determined 
from whole-cell voltage clamp recordings made in HEK cells stably expressing 
hERG channels. Structures and biological results of all these molecules are 
reported in Table 2. IC50 and pIC50values were calculated on a new extensive 
CoMFA model constructed on a broad training set of molecules.78 
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Table 2. Experimental and Predicted hERG K+ Channel Blocking Activity of 20-27. 
 
 
_________________________________________________________________________________________________________________
a
 tested as hydrochloride salts 
 
As displayed in the Table 2, the most potent inhibitor effect was expressed by 
compound 25, that exhibited a nanomolar activity. Thus, basing on this promising 
compound, further computational investigation were performed, with the aim to 
design synthesize a new series of molecules and to enhance the SAR studies 
previously reported.78 
 
The rational design of new compounds took into account several modifications 
that could build up their effectiveness in blocking hERG channels. It was 
suggested to introduce different groups on aromatic rings corresponding to C0 and 
C1 pharmacophoric points (Figure 36, A) to obtain either mono- or di- substituted 
derivatives. Withdrawing or donating groups could be insert in place of fluorine 
atom. Moreover the fluorine moiety could be substituted by a chlorine, a largest 
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halogen. Further modifications involved ethylenic chain extension and the 
transformation of secondary amine group in a tertiary ones (Figure 36, B). 
 
 
 
 
A                                                                       B 
 
Figure 36. (A) Pharmacophore model of hERG K+ channel blockers. (B) General 
structure of new hERG blockers.  
 
To obtain the new compounds, in order to improve the reaction rate and yield, 
MAOS was applied. The retrosynthetic analysis (Scheme 6) suggested a direct N-
alkylation of the proper substituted amines 28-34 with commercially available 1-
chloro-3-phenylpropane 35 to reach the desired new derivatives 36-42 (Table 3). 
The selective N-monoalkylation was ensured using an excess of amine and 
potassium iodide as a catalyst in the presence of potassium carbonate as a base.149 
  
n= 2
R1= -F, -Cl , -OCH3, -NH2, -NO2
R2= R3= -H
n= 2
R1= R2= -Cl , -OCH3, -NH2, -NO2
R3= -H
n= 2
R1= -F
R2= R3= -H
R3= -Met, -Et, -iPr
n= 2
R1= R2= -F
R3= -Met, -Et, -iPr
n= 3
R1= R2= -F
R3= -H
n= 3
R1= -F
R2= R3= -H
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SCHEME 6a 
 
 
 
aReagents and conditions: K2CO3, KI, DMF, 110° C, 150 W, 10 min. 
 
 
Table 3. New hERG blockers. 
Entry Amines Final Product 
1 
 
 
28  
36 
2 
 
 
29  
37 
62 
3 
 
 
30  
38 
4 
 
 
31  
39 
5 
 
 
32  
40 
6 
 
 
33  
41 
7 
 
 
34 
 
 
42 
63 
The N1-diphenyl-N2-alkyl amines 28-34 were obtained by a general synthetic 
procedure described as following. The alkylation reaction of the appropriate 
diphenyl amines 43-48 provided the N-diphenylalkylchlorides 49-55. These 
chloroalkyl-derivatives underwent a Gabriel synthesis,150 that proceeded through 
two synthetic steps. Firstly, the treatment of 49-55 with potassium phtalimide 
gave a N-alkylphatalimide derivatives 56-62 which were cleaved with hydrazine 
hydrate,151 to obtain the desired N1-diphenyl-N2-alkyl amines 28-34.  
The alkylation of the amines 43-48 followed two different synthetic routes 
depending on the introduction of an ethylenic or propylenic chain. The 
chloroethyl derivatives 49-53 was achieved under conventional heating using 2-
chloroethyl tosylate and n-Butil litium,152 54 and 55, were obtained by an 
alkylation reaction conducted under microwave irradiation,153 in which the 
diphenyl amines 43 and 48 were treated firstly with NaH then alkylated with 1-
Bromo-3-Chloropropane.  
Among the used diphenylamine, 43, 44, 45 and 48, were synthesized taking 
advantage of an improvement154,155 of Buchwald-Hartwig cross-coupling,156 while 
46 and 47 were commercially available. In the Buchwald coupling reaction a 
direct Pd-catalyzed C-N bond formation between appropriate aromatic amines 63-
64 and aryl halides 65-67 took place in the presence of 1,1'-bis-
(diphenylphosphinino)ferrocene (dppf) as phosphine type ligand. This synthetic 
procedure produced the desired amines in good yield.(Scheme 7).  
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Scheme 7a 
 
 
 
aReagents and conditions: a) DPPF, DPPF PdCl2• CH2Cl2, Na-t-But, THF dry, 100° C, 
3-5 h. b) n-BuLi, 2-chloroethyltosylate, Et2O dry, r.t., 28 h; c) Step1: NaH, THF dry, 130° 
C, 200 W, 40 min; Step 2: 1-Bromo-3-Cloropropano, 120° C, 200 W, 21 min; d) 
potassium phatlimide, DMF dry, reflux, 6-9 h; e) hydrazina hydrate, EtOH, reflux. 
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3. Biological Evaluation 
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As explained in the introduction, my PhD project was distinct by two main 
research tasks. The first one concerned the synthesis of natural product-like small 
molecules, potentially able to interfere with the cell cycle progression in tumor 
cells.  
The second project involved the rational design and synthesis of small 
molecules endowed with the minimally structured requirements to bind and block 
the hERG K+ channel, a well-known biomarker of cardiotoxicity. 
In this chapter, preliminary available biological data of both the libraries are 
shown and discussed.  
A detailed description of analysis procedures used for testing the compounds is  
reported in the experimental section. 
 
 
3.1 Preliminary Biological Resultsfor the antiproliferative activity of  
hybrid compounds on Bcr-Abl expressing K562 cells. 
 
The first project was aimed to the construction of hybrid molecules resulting 
from the merge of spiro- or poly-cyclic cores, as natural-like scaffolds, with bi- 
and ter-phenyl fragments, as biologically validated moiety (Chart 2 and Schemes 
4-5). This work has represented an extension of the existing small molecules 
library, that showed interesting biological activity in sensitive HL60 and Brc-Abl-
expressing K562 cells.129,137 
The new synthesized hybrid molecules 12a-m and 16a-c are currently tested in 
the laboratory of Dr Tolomeo, at the Interdepartmental Center of Research in 
Clinical Oncology (CIROC) of the University of Palermo. 
The antiproliferative activity of each compound in K562 cells was evaluated 
after 48 hours by counting cells with an automatic cell counter and was expressed 
as IC50 (concentration inhibiting 50% of cell growth). The data are shown in 
Table 4. Spirocyclic 1-4 are included for comparison with the previous collection. 
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Table 4. IC50a (µM ± SE) values in Bcr-Abl-expressing K562 cells of new synthesized 
compounds 12a-m and 16a-c in comparison with 1-4 previously obtained. 
Compound IC50a (µM) Compound IC50
a   
(µM) 
 
1b 
 
 
 
8±1 
 
12f 
10±1 
 
2b 
8±1 
 
12g 
9±1 
 
3b 
14±2 
 
12h 
>50 
 
4b 
9±1 
 
12i 
>50 
N
N
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CH3
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O
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O
O
O
O
O
O
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MeO
OMe
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12a 
30±1 
 
12l 
38±3 
 
12b 
N. D. 
 
12m 
13±1 
 
12c 
N. D. 
 
 
16a 
>50 
 
12d 
N. D. 
 
 
16b 
20±2 
 
12e 
>50 
 
 
16c 
>50 
a
 concentration able to inhibit 50% of cell growth after 48 h of treatment. 
b
 compounds previously synthesized 
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On the basis of these biological results, some preliminary considerations about 
the structural features relevant in conferring antiproliferative activity of the new 
molecules, with respect to the parent compounds, could be allow. 
The hybrid derivatives, 12f, 12g and 12m, whose spirocyclic portion is 
represented by a cis-2,4-dimethyl-2,4-diazaspiro[5,5]undecane-1,3,5,9-tetraone 
showed to maintain a comparable activity respect to the parent compounds 1-2, 3 
and 4 respectively. This could suggest that a substitution of 1,3-dicarbonyl 
fragments does not affect the biological profile.  
Regarding the biphenyl derivatives differently substituted in the phenyl rings, 12e, 
bearing a para-trifluoromethyl group, displayed a drop of activity (IC50 > 50 µM) 
compared to the para-hydroxy substituted compound 2 (IC50 = 8 µm). This could 
be due to the absence of hydroxyl function arranged in para-position on the latest 
aromatic ring, probably relevant to exert the biological activity. Similarly 
compound 12a, bearing a para-aldeyde function, showed a lower activity (IC50 = 
30 µm) compared to its parent compounds 1 and 3 endowed respectively with a 
para-hydroxy or para-methylhydroxy groups. Based on these results a crucial 
determinant of the high antiproliferative activity seems to be the presence of the 
para-hydroxy function. 
Regarding the terphenyl derivatives, a decrease activity was observed for 
compounds 12h (IC50 > 50 µM) endowed with metoxy groups in meta-position on 
the aromatic moieties, and for the branched terphenyls 12i (IC50 > 50 µM) and 12l 
(IC50 = 38 µm). These data could be suggest the positive influence of linear-
oriented aromatic rings. Furthermore the slightly better activity of 12l with respect 
to 12i, could be due to the presence of a polar para-oriented carboxylic group.  
All the polycyclic derivatives 16a-c, showed lower antiproliferative activity 
respect to the spirocyclic compounds. These results suggest that the increased 
complexity of the natural like core decrease the activity. 
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3.2 Preliminary Biological Results for hERG K+ current inhibition of 
“Minimally Structured hERG Blockers” on HEK cells stably expressing 
hERG channels. 
 
The second project developed during my PhD, representing an improvement of 
an our previous work,78 regarding the design and synthesis of “minimally 
structured hERG blockers”, with the purpose of enhancing the SAR studies and to 
gain more insight to drug-induced hERG blockade mechanism.  
A first small set of molecules 20-27 (Table 2) endowed with the minimally 
structured requirements to bind and block hERG K+ channel, was previously 
synthesized by us.78 
The capability of hERG K+ current inhibition of 20-27 was determined from 
whole-cell voltage clamp recordings made in HEK cells stably expressing hERG 
channels. Structures and biological results of all these molecules are reported in 
Table 2. IC50 and pIC50values were calculated on a new extensive CoMFA model 
constructed on a broad training set of molecules.78 
Thus, basing on this promising compound, further computational investigation 
were performed, with the aim to design and synthesize a new series of molecules 
and to enhance the SAR studies previously reported.78 
The rational design of new compounds took into account several modifications 
that could build up their effectiveness in blocking hERG channels. 
The new synthesized hybrid molecules 36-42 are currently tested in the laboratory 
of Prof. Mitcheson, at the Department of Cell Physiology and Pharmacology, 
University of Leicester, United Kingdom.  
Some preliminary biological results are reported in Table 5, included compound 
25, the most potent inhibitor of the previous series for comparison, furthermore a 
brief discussion was reported. 
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Table 5. Experimental hERG K+ Channel Blocking Activity in comparison with 25 
previously obtained. 
Compounda IC50 (nM) pIC50exp Compounda IC50 (nM) pIC50exp 
 
 
25 
2.4 8.6±0.08 
 
 
39 
4.8 8.3±0.08 
 
 
36 
1.5 8.8±0.11 
 
 
40 
N. D. N. D. 
 
 
37 
4.7 8.3±0.10 
 
 
41 
N. D. N. D. 
 
 
38 
N. D. N. D. 
 
 
42 
N. D. N. D. 
a
 tested as hydrochloride salts 
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The CoMFA model reported in Figure 35 showed that sterically favorable 
regions are located around the pharmacophoric points C1 and mostly C2, while 
the space around C0 seems sensitive to both steric and electrostatic properties of 
the molecules. Particularly, increasing bulk is detrimental for the activity, while 
the presence of positively and negatively charged groups, indicate a prevalent 
favorable effect. On the basis of this CoMFA model, some preliminary 
consideration can be given. 
Among the firstly tested compounds 36-37 and 39, 36 showed an IC50 of 1.5 nM,  
thus representing a more potent inhibitor compared with its parent compound 25 
(IC50 = 2.4 nM). 
This data suggested that one fluorine moiety it is sufficient to give a relevant 
blocking activity. 
37 and 39 revealed less active if related to 25, showing an IC50 value of 4.7 nM, 
nevertheless their inhibitor activity is higher if compared with the derivatives 
obtained from the previous series. These results suggested that the substitution of 
the fluorine atoms in C0 and C1 position, with chlorine or methoxy groups, 
respectively in 37 and 39, did not affect in a relevant manner the blocking 
potency. 
  
73 
 
 
 
 
 
 
 
 
 
 
 
 
4. Conclusions 
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The central core of my PhD regarding the design and synthesis of biologically 
actives small molecules, which could be consider either potential lead candidates 
or valuable chemical tools to dissect biological systems, included two main 
research lines. 
As a follow-up of a previous work, my first project dealt with the design and 
synthesis of natural product-like small molecules potentially able to interfere with 
pathways involved in cancer cells. Inspired by Biology-Oriented Synthesis I took 
advantage of a two step synthetic route relying on the combination of Domino 
Knoevenagel/Diels Alder (click reaction), for the construction of the natural 
product-like cores, with Suzuki coupling for the derivatization step. I 
demonstrated that this platform is amenable to parallel library generation allowing 
to enhance the structural diversity and complexity of the existing collection. 
Several obtaining newly-substitued hybrid compounds were obtained with good 
yield.  
From the preliminary biological results, some derivatives showed to maintain a 
comparable biological activity, respect to their parent compounds, indicating that 
the presence of an hydroxylic function in para-position is relevant for the 
biological effect. Indeed a decreased antiproliferative activity was observed when 
the hydroxylic function was substituted by a methoxy or trifluoromethyl groups or 
increasing the complexity of the natural like core. 
The generation of this new library has contributed to outline the common 
structural features responsible for the expression of the biological activity. 
The second project regarded the rational design and synthesis of minimally 
structured hERG blockers, with the purpose of improve the previous collection 
prepared by us. Starting from a Target-oriented Synthesis, a small set of new 
hERG blockers was achieved using either conventional and microwave heating. 
The microwave assisted synthetic procedures afforded the desired new products 
with several advantages. Firstly rate enhancement and increased yield: reaction 
times reduced drastically from hours to minutes and minimized occurrence of 
unwanted side reaction. Furthermore a great reproducibility and the possibility to 
perform the reactions in a solvent-free conditions, according to the principles of 
Green Chemistry. The obtained compounds are currently tested for their 
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capability to bind and block the hERG K+ channel and from the preliminary 
biological results, they showed a more relevant blocking activity compared with 
the derivatives of the first series. 
The new small set of hERG blockers, was able to gain more insight to the 
minimal structural requirements for hERG liability, which is mandatory to 
investigate in order to reduce the risk of potential side effects of new drug 
candidates. 
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5. Experimental Section 
  
77 
General Chemical Methods 
Reactions progress was monitored by thin layer chromatography (TLC) using 
commercially prepared glass plates pre-coated with Merck silica gel 60 F254. 
Adsorbed compounds were viewed by the quenching of UV fluorescence (λmax = 
254 nm). Purification of compounds by column chromatography was achieved 
using slurry-packed Merck 9385 Kieselgel 60 silica gel (230-400 mesh). All 
solvents were distilled prior to use, except those used for Suzuki coupling 
reactions. All reagents were obtained from commercial sources and used without 
further purification. Unless otherwise stated, all reactions were carried out under 
an inert atmosphere. Compounds were named relying on the naming algorithm 
developed by Cambridge Soft Corporation and used in Chem-BioDraw Ultra 11.0. 
Reactions involving microwave irradiation were performed using a focused 
single-mode microwave synthesis system (CEM Discover® SP, 2.45GHz, 
maximum power 300 W), equipped with infrared temperature measurement. 1H-
NMR and13C-NMR spectra were recorded on Varian Gemini at 200-300-400 
MHz and 50-75-100 MHz respectively. Chemical shifts (δH) are reported relative 
to TMS as internal standard. Mass spectrum was recorded on a V.G. 7070E 
spectrometer or on a Waters ZQ 4000 apparatus operating in electrospray (ES) 
mode. 
 
 
5.1  Natural product-like small molecules library 
 
5.1.1  Spirocyclic derivatives 
 
General Parallel Procedure for Bromo-biphenylcarbaldehyde Synthesis 
To a solution of o-, or p-iodobromobenzene (1 equiv) in 1 mL of toluene is 
added a catalytic amount (3-5% mol) of tetrakis-triphenylphosphine palladium 
and 0.3 mL of aqueous 2M Na2CO3. A solution of 4-formyl-benzeneboronic acid 
(1.6 equiv) in 1 mL of ethanol is then added, and the mixture is heated to reflux 
for 3 hours in an argon atmosphere. After cooling, the mixture is extracted three 
times with dichloromethane and the joined organic phases are washed with water 
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and brine, dried, and evaporated under vacuum. The residue is purified by flash 
chromatography, giving the bromodiphenylaldehyde derivative. 
 
 
3'-bromo-[1,1'-biphenyl]-4-carbaldehyde 6b 
6b was prepared as previously described starting from o-
iodobromobenzene (120 mg, 0.42 mmol). The residue was 
purified by flash chromatography, eluting with 9.7: 0.3 
petroleum ether: EtOAc. 
6b: 0.05 g (yield 50 %), colourless oil; 1H NMR (200 MHz, CDCl3) δ 7.37 (d, J= 
7.7 Hz, 1H), 7.57 (m, 2H), 7.72 (d, J = 9.2 Hz, 2H), 7.77 (m, 1H), 7.96 (d, J = 9 
Hz, 2H), 10.07 (s,1H). 
 
 
4'-bromo-[1,1'-biphenyl]-4-carbaldehyde 6c 
6c was prepared as previously described starting from o-
iodobromobenzene (0.5 g, 1.77 mmol). The residue was 
purified by flash chromatography, eluting with 9.65: 0.35 
petroleum ether: EtOAc. 
6c: 0.3 g (yield 65%), white powder; 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 
8.6 Hz, 2H), 7.56 (d, J = 8.6 Hz, 2H), 7.69 (d, J = 8 Hz, 2H), 7.93 (d, J = 8 Hz, 
2H), 10.04 (s, 1H). 
 
 
General parallel procedure for (K-DA-E) Domino-Knoevenagel Diels 
Alder reaction (intermolecular fashion) 
In distinct reactors equipped with a magnetic stirring bar, a mixture of 1 mmol 
(1.0 equiv.) of the appropriate aromatic aldehyde 6a-c and 1 mmol of proper 
active methylene compounds 5a-c (1.0 equiv) in MeOH were prepared and then 
the catalyst (L)-5,5-dimethyl thiazolidinium-4-carboxylate (L-DMTC) (0.2 equiv) 
was added to each reactor. The resulting mixtures were stirred for 30 min at 
ambient temperature, then (E)-4-phenyl-3-buten-2-one 9 (2.0 equiv) was added to 
each reaction mixtures and the suspensions were allowed to stir at room 
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temperature for 72 h. Each crude reaction was diluted with dichloromethane and 
treated with saturated aqueous ammonium chloride solution. The layers were 
separated and the aqueous phase was further extracted with dichloromethane (3 × 
15 mL). The combined organic layers were dried over Na2SO4 and evaporated 
under reduced pressure. Each crude Diels-Alder product was purified by flash 
chromatography (petroleum ether/EtOAc). The enantiomeric excesses of the 
purified products have not been determined. The cis stereochemistry of the 
compounds was established by NOESY analysis (data not shown). 
 
 
(2R,6S)-2-(4-bromophenyl)-6-phenylspiro[cyclohexane-1,2'-indene]-1',3',4-
trione 10a 
This product was obtained according to the general parallel 
procedure for K-DA-E described above using the commercial 
aldehyde 6a (0.70 g, 3.78 mmol) and the 1,3-indandione 5a. The 
crude product was purified by flash chromatography, eluting 
with 9.5: 0.5 petroleum ether: EtOAc. 
10a: 1.56 g (yield 90 %), solid crystalline; 1H NMR (300 MHz, C6D6) δ 2.43 
(ddd, J = 1.8, 3.6, 14.4 Hz, 1H), 2.52 (ddd, J = 1.8, 3.6, 14.4 Hz, 1H), 3.42 (dd, J 
= 1.8, 14.4 Hz, 1H), 3.51 (dd, J = 4.2, 14.4 Hz, 1H), 3.58 (t, J = 14.4 Hz, 1H), 
3.68 (t, J = 14.4 Hz, 1H), 6.35 (t, J = 7.2 Hz, 1H), 6.47 (t, J = 7.2 Hz, 1H), 6.56 (t, 
J = 7.2 Hz, 1H), 6.64-6.68 (m, 4H), 6.80-6.82 (m, 2H), 6.96 (d, J = 7.8 Hz, 2H), 
7.03 (d, J = 7.2 Hz, 1H), 7.27 (d, J = 7.2 Hz, 1H). 13C NMR (75 MHz, C6D6) δ 
43.2, 47.7, 48.8, 61.7, 121.5, 122.0, 122.4, 127.6 , 127.8 (CH), 128.3 (CH), 129.7 
(CH), 131.4, 135.4, 136.5, 137.0, 141.7, 142.5, 201.5, 203.1, 207.6. 
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(7R,11S)-7-(4-bromophenyl)-3,3-dimethyl-11-phenyl-2,4-
dioxaspiro[5.5]undecane-1,5,9-trione 10b 
This product was obtained according to the general parallel 
procedure for K-DA-E described above using the commercial 
aldehyde 6a (0.5 g, 2.70 mmol) and the Meldrum’s acid 5b. The 
crude product was purified by flash chromatography, eluting 
with 9.5: 0.5 petroleum ether: EtOAc. 
10b: 0.92 g (yield 74 %), crystalline white powder; 1H NMR (300 MHz, C6D6) δ 
0.52 (s, 3H), 0.66 (s, 3H), 2.33 (dd, J = 4.2, 15 Hz, 1H), 2.41 (dd, J = 4.2, 15 Hz, 
1H), 3.38 (t, J = 9 Hz, 1H), 3.51 (t, J = 9 Hz, 1H), 3.57 (dd, J = 4.2, 14.4 Hz, 1H), 
3.8 (dd, J = 4.2, 14.4 Hz, 1H), 6.76 (d, J = 9 Hz, 2H), 6.81-6.83 (m, 1H), 6.86-
6.89 (m, 2H), 7.02-7.05 (m, 2H), 7.04 (buried d, J = 9 Hz, 2H). 13C NMR (75 
MHz, C6D6) δ 28.2, 28.6, 42.7, 42.8, 49.6, 49.9, 60.3, 106.5, 122.7, 128.4, 128.8, 
129.3, 130.1, 132.3, 136.1, 136.9, 165.1, 168.0, 206.9. 
 
 
(7R,11S)-7-(4-bromophenyl)-2,4-dimethyl-11-phenyl-2,4-
diazaspiro[5.5]undecane-1,3,5,9-tetraone 10c 
This product was obtained according to the general parallel 
procedure for K-DA-E described above using the aldehyde 6a 
(0.2 g, 1.01 mmol) and the 1,3-dimethylbarbituric acid 5c. The 
crude product was purified on silica eluting with 9: 1 
petroleum ether: EtOAc.  
10c: 0.207 g (yield 44 %), white fine powder; 1H NMR (400 MHz, CDCl3) δ 
2.56-2.62 (m, 2H), 2.86 (s, 3H), 3.01 (s, 3H), 3.60-3.74 (m, 2H), 3.92 (dd, J = 4 
Hz, 16H, 1H), 4.03 (dd, J = 4 Hz, 16H, 1H), 6.95-7.02 (m, 4H), 7.21-7.23 (m, 
3H), 7.34-7.36 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 28.1, 28.5, 42.7, 43.1, 
49.3, 51.3, 60.8, 122.7, 127.4, 128.9, 129, 129.6, 132.2, 136.6, 136.7, 149.6, 
168.9, 170.6, 207.6. 
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(7R,11S)-7-(3'-bromo-[1,1'-biphenyl]-4-yl)-3,3-dimethyl-11-phenyl-2,4-
dioxaspiro[5.5]undecane-1,5,9-trione 10d 
This product was obtained according to the general parallel 
procedure for K-DA-E described above using the aldehyde 6b 
(0.24 g, 0.92 mmol) and the Meldrum’s acid 5b. The crude 
product was purified by flash chromatography, eluting with 9.3: 
0.7 petroleum ether: EtOAc. 
10d: 0.24 g (yield 49 %), white powder; 1H NMR (300 MHz, 
CDCl3) δ 0.56 (s, 3H), 0.61 (s, 3H), 2.63-2.65 (m, 1H), 2.70-2.72 (m, 1H), 3.67-
3.82 (m, 2H), 4.00-4.05 (m, 1H), 4.07-4.12 (m, 1H), 7.23-7.35 (m, 8H), 7.43-7.56 
(m, 4H), 7.66-7.68 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 28.3, 28.4, 42.8, 49.8, 
50.0, 60.5, 106.4, 123.0, 125.5, 127.7, 128.4, 128.7, 129.0, 129.2, 129.9, 130.4, 
130.6, 136.7, 137.0, 140.0, 142.0, 165.2, 168.1, 207.4. 
 
 
(7R,11S)-7-(4'-bromo-[1,1'-biphenyl]-4-yl)-2,4-dimethyl-11-phenyl-2,4-
diazaspiro[5.5]undecane-1,3,5,9-tetraone 10e 
This product was obtained according to the general parallel 
procedure for K-DA-E described above using the aldehyde 
6c (0.22 g, 0.92 mmol) and the 1,3-dimethylbarbituric acid 
5c. The crude product was purified by flash 
chromatography, eluting with 9.1: 0.9petroleum ether: 
EtOAc. 
10e: 0.23 g (yield 50 %), pale-yellow powder; 1H NMR (400 MHz, CDCl3) δ 
2.60-2.65 (m, 2H), 2.87 (s, 3H), 3.03 (s, 3H), 3.66-3.81 (m, 2H), 3.98 (d, J = 4 Hz, 
1H), 4.07 (d, J = 4 Hz, 1H), 7.03-7.06 (m, 2H), 7.13-7.15 (m, 2H), 7.23-7.24 (m, 
3H), 7.35-7.42 (m, 4H), 7.51-7.53 (m, 2H).13C NMR (75 MHz, CDCl3) δ28.1, 
28.5, 42.9, 43.2, 49.8, 51.1, 61.0, 122.1, 127.4, 128.3, 128.5, 132.0, 136.3, 137.00, 
139.0, 140.2, 149.7, 169.1, 170.8, 208.0, 208.2. 
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General parallel procedure for Suzuki coupling  
In distinct reactors, to a solution of the appropriate bromine derivative 10a-e 
(1.0 equiv) in PhMe (9 mL), aqueous Na2CO3 (2M, 3.0 equiv) and the suitable 
boronic acid 11a-h (2.0 equiv) dissolved in EtOH (3 mL) were added. Each 
reaction mixture was deoxygenated with a stream of N2 for 10 min and then 
Pd(Ph3P)4 (0.05 equiv) was added. The mixtures were heated to reflux for 5-6 
hours, then cooled to room temperature and treated as follows. Each solution was 
poured into a mixture of H2O and Et2O, and the phases were separated. The 
aqueous layer was extracted with Et2O (3 × 15 mL) and the combined ethereal 
phases were washed with 1M NaOH and brine. The organic layer was dried over 
Na2SO4 and evaporated. Each crude product was purified by flash 
chromatography. 
 
 
4'-((2S,6R)-1',3',4-trioxo-2-phenyl-1',3'-dihydrospiro[cyclohexane-1,2'-
inden]-6-yl)-[1,1'-biphenyl]-4-carbaldehyde 12a 
This product was achieved following the general synthetic 
procedure for Suzuki Coupling described above. The 
spiroderivative 10a (0.26 g, 0.56 mmol) was allowed to react 
with the phenyl boronic acid 11a. The crude product was 
purified by flash chromatography, eluting with 8: 2petroleum 
ether: EtOAc. 
12a: 0.22 g (yield 80 %), white powder; 1H NMR (300 MHz, CDCl3) δ 2.65-2.76 
(m, 2H), 3.79-3.96 (m, 4H), 6.96-7.03 (m, 5H), 7.18 (d, J = 8.1 Hz, 2H), 7.32 (d, J 
= 8.1 Hz, 2H), 7.42-7.47 (m, 2H), 7.50-7.54 (m, 3H), 7.69 (d, J = 7.5 Hz, 1H), 
7.85 (d, J = 9 Hz, 2H), 9.99 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 43.2, 43.3, 
48.1, 48.9, 61.9, 122.1, 122.4, 127.1, 127.2, 127.6, 127.9, 128.3, 128.7, 128.9, 
130.0, 135.1, 135.3, 137.1, 137.9, 138.6, 141.8, 142.6, 145.9, 191.6, 201.6, 203.2, 
207.9. 
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(2R,6S)-2-(3',5'-dimethoxy-[1,1'-biphenyl]-4-yl)-6-phenylspiro[cyclohexane-1,2'-
indene]-1',3',4-trione 12b 
This product was achieved following the general synthetic 
procedure for Suzuki Coupling described above. The 
spiroderivative 10a (0.2 g, 0.43 mmol) was allowed to 
react with the phenyl boronic acid 11b. The crude product 
was purified by flash chromatography, eluting with 9: 1 
petroleum ether: EtOAc. 
12b: 0.09 g (yield 40 %), white powder; 1H NMR (300 MHz, CDCl3) δ 2.67-2.71 
(m, 2H), 3.78 (s, 6H), 3.78-3.90 (m, 4H), 6.40 (t, J = 2 Hz, 1H), 6.51 (d, J = 2 Hz, 
2H), 6.98-7.12 (m, 6H), 7.23-7.28 (m, 2H), 7.42-7.51 (m, 3H), 7.65-7.69 (m, 1H). 
13C NMR (75 MHz, CDCl3) δ 43.3, 43.4, 48.3, 48.8, 55.3, 62.0, 99.1, 105.0, 
122.1, 122.4, 127.0, 127.6, 128.0, 128.3, 128.4, 135.3, 136.8, 137.2, 140.0, 141.9, 
142.2, 142.7, 160.9, 201.8, 203.4, 208.3. 
 
 
4'-((7R,11S)-3,3-dimethyl-1,5,9-trioxo-11-phenyl-2,4-dioxaspiro[5.5]undecan-7-yl)-
[1,1'-biphenyl]-4-carbaldehyde 12c 
This product was achieved following the general synthetic 
procedure for Suzuki Coupling described above. The 
spiroderivative 10b (0.2 g, 0.44 mmol) was allowed to react 
with the phenyl boronic acid 11a. The crude product was 
purified by flash chromatography, eluting with 9: 1 petroleum 
ether: EtOAc. 
12c: 0.07 g (yield 33 %), pale-yellow powder; 1H NMR (300 MHz, CDCl3) δ 0.57 
(s, 3H), 0.64 (s, 3H), 2.68-2.73 (m, 2H), 3.77 (dt, J = 3, 15 Hz, 2H), 4.09 (dt, J = 
4.5, 15 Hz, 2H), 7.26-7.35 (m, 5H), 7.39 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 
2H), 7.72 (d, J = 8.4 Hz, 2H), 7.97 (d, J = 8.4 Hz, 2H), 10.07 (s, 1H). 13C NMR 
(75 MHz, CDCl3) δ 28.2, 28.4, 42.7, 42.8, 49.8, 49.9, 60.4, 106.4, 127.4, 127.9, 
128.4, 128.7, 129.1, 129.2, 130.3, 135.4, 136.9, 137.3, 140.0, 145.8, 165.2, 168.1, 
191.7, 207.2.  
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(7R,11S)-7-(3',5'-dimethoxy-[1,1'-biphenyl]-4-yl)-3,3-dimethyl-11-phenyl-2,4-
dioxaspiro[5.5]undecane-1,5,9-trione 12d 
This product was achieved following the general synthetic 
procedure for Suzuki Coupling described above. The 
spiroderivative 10b (0.2 g, 0.44 mmol) was allowed to react 
with the phenyl boronic acid 11b. The crude product was 
purified by flash chromatography, eluting with 8.5: 1.5 
petroleum ether: EtOAc. 
12d: 0.13 g (yield 57 %), white crystalline powder; 1H NMR (300 MHz, CDCl3) δ 
0.58 (s, 3H), 0.63 (s, 3H), 2.67-2.69 (m, 1H), 2.71-2.74 (m, 1H), 3.72-3.86 (m, 
2H), 3.86 (s, 6H), 4.04-4.12 (m, 2H), 6.50 (t, J = 2.4 Hz, 1H), 6.66-6.69 (m, 2H), 
7.29-7.38 (m, 7H), 7.57-7.60 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 28.3, 42.8, 
49.8, 49.9, 55.3, 60.5, 99.3, 105.2, 106.4, 127.7, 128.4, 128.7, 128.8, 129.2, 136.2, 
137.0, 141.4, 142.1, 161.1, 165.2, 168.2, 207.5. 
 
 
(7S,11R)-3,3-dimethyl-7-phenyl-11-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-2,4-
dioxaspiro[5.5]undecane-1,5,9-trione 12e 
This product was achieved following the general synthetic 
procedure for Suzuki Coupling described above. The 
spiroderivative 10b (0.1 g, 0.22 mmol) was allowed to react 
with the phenyl boronic acid 11c. The crude product was 
purified by flash chromatography, eluting with 9.5: 0.5 
petroleum ether: EtOAc. 
12e: 0.07 g (yield 61 %), white powder; 1H NMR (300 MHz, CDCl3) δ 0.56 (s, 
3H), 0.62 (s, 3H), 2.64-2.67 (m, 1H), 2.72-2.74 (m, 1H), 3.76 (dt, J = 2, 15 Hz, 
2H), 4.01-4.14 (m, 2H), 7.23-7.39 (m, 7H), 7.58-7.72 (m, 6H).13C NMR (75 MHz, 
CDCl3) δ 28.2, 28.3, 42.7, 42.8, 49.8, 49.9, 60.5, 106.4, 125.8, 127.2, 127.8, 
128.4, 128.7, 129.1, 129.2, 137.0, 140.0, 143.4, 165.2, 168.1, 207.3. 
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(7R,11S)-7-(4'-hydroxy-[1,1'-biphenyl]-4-yl)-2,4-dimethyl-11-phenyl-2,4-
diazaspiro[5.5]undecane-1,3,5,9-tetraone 12f 
This product was achieved following the general synthetic 
procedure for Suzuki Coupling described above. The 
spiroderivative 10c (0.3 g, 0.64 mmol) was allowed to react 
with the phenyl boronic acid 11d. The crude product was 
purified by flash chromatography, eluting with 8: 
2petroleum ether: EtOAc. 12f: 0.2 g (yield 65 %), pale 
yellow oil; 1H NMR (400 MHz, CDCl3) δ 2.61-2.66 (m, 2H), 2.87 (s, 3H), 3.02 (s, 
3H), 3.68-3.8 (m, 2H), 3.98-4.08 (m, 2H), 5.34 (s, 1H), 6.85-6.87 (m, 2H), 7.04-
7.11 (m, 4H), 7.22-7.24 (m, 3H), 7.37-7.40 (m, 4H). 13C NMR (100 MHz, CDCl3) 
δ 28.1, 28.5, 42.9, 43.2, 50.0, 50.9, 61.0, 115.9, 127.1, 127.5, 128.1, 128.2, 128.3, 
128.4, 128.8, 128.9, 129.0, 132.7, 135.6, 137.1, 141.0, 149.8, 155.7, 169.1, 170.8, 
208.7. 
 
 
(7R,11S)-7-(4'-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)-2,4-dimethyl-11-phenyl-2,4-
diazaspiro[5.5]undecane-1,3,5,9-tetraone 12g 
This product was achieved following the general synthetic 
procedure for Suzuki Coupling described above. The 
spiroderivative 10c (0.3 g, 0.64 mmol) was allowed to react 
with the phenyl boronic acid 11e. The crude product was 
purified by flash chromatography, eluting with 8: 2 
petroleum ether: EtOAc. 12g: 0.15 g (yield 57 %), colorless 
oil; 1H NMR (400 MHz, CDCl3) δ 2.59-2.64 (m, 2H), 2.86 
(s, 3H), 3.02 (s,3H), 3.66-3.79 (m, 2H), 3.96-4.07 (m, 2H), 4.70 (s, 2H), 7.03-7.06 
(m, 2H), 7.11-7.13 (m, 2H), 7.21-7.24 (m, 3H), 7.39-7.44 (m, 4H), 7.48-7.50 (m, 
2H).13C NMR (100 MHz, CDCl3) δ 28.1, 28.5, 42.9, 43.2, 49.9, 50.9, 60.9, 65.1, 
127.2, 127.3, 127.5, 127.6, 128.2, 128.8, 128.9, 136.4, 137.0, 139.4, 140.5, 141.0, 
149.7, 169.1, 170.8, 208.3.  
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(7S,11R)-3,3-dimethyl-7-phenyl-11-(3',3'',5''-trimethoxy-[1,1':4',1''-terphenyl]-4-yl)-
2,4-dioxaspiro[5.5]undecane-1,5,9-trione 12h 
This product was achieved following the general 
synthetic procedure for Suzuki Coupling described 
above. The spiroderivative 10b (0.2 g, 0.7 mmol) was 
allowed to react with the phenyl boronic acid 11f. The 
crude product was purified by flash chromatography, 
eluting with CHCl3.  
12h: 0.04 g (yield 20 %), pale-yellow powder; 1H NMR 
(300 MHz, CDCl3) δ 0.60 (s, 3H), 0.68 (s, 3H), 2.68-2.77 (m, 2H), 3.74-3.84 (m, 
2H), 3.86 (s, 6H), 3.91 (s, 3H), 4.05-4.15 (m, 2H), 6.51 (t, J = 1.8, 1H), 6.73-6.74 
(m, 2H), 7.16 (m, 1H), 7.21-7.31 (m, 4H), 7.36-7.44 (m, 5H), 7.65-7.68 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 28.3, 28.4, 42.8, 49.8, 49.9, 55.3, 55.7, 60.5, 99.2, 
106.4, 107.7, 109.8, 119.3, 127.7, 128.4, 128.7, 128.9, 129.2, 130.1, 131.1, 136.2, 
137.0, 139.8, 140.6, 141.2, 156.7, 160.3, 165.2, 168.2, 207.5. 
 
 
(7R,11S)-7-(4''-methoxy-[1,1':3',1''-terphenyl]-4-yl)-3,3-dimethyl-11-phenyl-
2,4-dioxaspiro[5.5]undecane-1,5,9-trione 12i 
This product was achieved following the general synthetic 
procedure for Suzuki Coupling described above. The 
spiroderivative 10d (0.17 g, 0.32 mmol) was allowed to react 
with the phenyl boronic acid 11g. The crude product was 
purified by flash chromatography, eluting with 8.5: 1.5 
petroleum ether: EtOAc.  
12i: 0.12 g (yield 67 %), white powder; 1H NMR (300 MHz, 
CDCl3) δ 0.60 (s, 3H), 0.66 (s, 3H), 2.68-2.77 (m, 2H), 3.80 (dt, J = 6, 15 Hz, 
2H), 3.90 (s, 3H), 4.06-4.15 (m, 2H), 7.03-7.05 (m, 2H), 7.31-7.39 (m, 7H), 7.50-
7.74 (m, 8H). 13C NMR (75 MHz, CDCl3) δ 28.3, 28.4, 42.8, 49.8, 50.0, 55.3, 
60.6, 106.4, 114.2, 125.2, 125.4, 126.1, 127.8, 128.2, 128.4, 128.7, 128.9, 129.2, 
129.3, 133.3, 136.1, 137.1, 140.5, 141.5, 141.6, 159.3, 165.2, 168.2, 207.5. 
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4''-((7R,11S)-3,3-dimethyl-1,5,9-trioxo-11-phenyl-2,4-dioxaspiro[5.5]undecan-7-yl)-
[1,1':3',1''-terphenyl]-4-carbaldehyde 12l 
This product was achieved following the general synthetic 
procedure for Suzuki Coupling described above. The 
spiroderivative 10d (0.17 g, 0.32 mmol) was allowed to react 
with the phenyl boronic acid 11h. The crude product was 
purified by flash chromatography, eluting with 9.5: 0.5 CHCl3: 
MeOH.  
12l: 0.11 g (yield 60 %), grey powder; 1H NMR (300 MHz, 
CD3OD) δ 0.61 (s, 3H), 0.67 (s, 3H), 2.57-2.67 (m, 2H), 3.65-
3.77 (m, 2H), 4.11-4.22 (m, 2H), 7.28-7.31 (m, 2H), 7.37-7.42 (m, 4H), 7.51-7.65 
(m, 2H), 7.71-7.85 (m, 4H), 7.91-7.94 (m, 2H), 8.02-8.05 (m, 1H), 8.16-8.20 (m, 
2H). 13C NMR (75 MHz, CD3OD) δ 28.5, 28.6, 43.4, 50.4, 50.5, 61.2, 106.9, 
126.5, 127.3, 127.5, 128.0, 128.5, 129.4, 129.9, 130.4, 130.5, 131.0, 133.7, 
1137.9, 138.6, 141.3, 141.6, 141.8, 165.9, 167.4, 168.7, 206.6. 
 
 
(7R,11S)-7-(4''-hydroxy-[1,1':4',1''-terphenyl]-4-yl)-2,4-dimethyl-11-phenyl-2,4-
diazaspiro[5.5]undecane-1,3,5,9-tetraone 12m 
This product was achieved following the general 
synthetic procedure for Suzuki Coupling described 
above. The spiroderivative 10e (0.15 g, 0.28 mmol) was 
allowed to react with the phenyl boronic acid 11d. The 
crude product was purified by flash chromatography, 
eluting with 7.2: 2.8 petroleum ether: EtOAc.  
12m: 0.11 g (yield 60 %), pale yellow powder; 1H NMR 
(300 MHz, CDCl3) δ 2.61-2.67 (m, 2H), 2.88 (s, 3H), 3.04 (s, 3H), 3.68-3.82 (m, 
2H), 3.98-4.11 (m, 2H), 4.75 (s, 1H), 6.89-6.91 (m, 2H), 7.05-7.07 (m, 2H), 7.14-
7.16 (m, 2H), 7.40-7.42 (m, 1H), 7.48-7.69 (m, 10H). 13C NMR (75 MHz, CDCl3) 
δ 28.0, 28.5, 42.9, 43.2, 50.0, 50.9, 61.0, 115.8, 127.1,127.3, 127.4, 127.5, 128.1, 
128.2, 128.8, 128.9, 132.4, 136.1, 137.0, 138.1, 140.5, 141.0 156.5, 169.1, 170.8, 
208.7.  
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5.1.2  Polycyclic derivatives 
 
SyntheticProcedure for 5-bromo-2-((3-methylbut-2-en-1-
yl)oxy)benzaldehyde 13140 
To a solution of 5-bromosalicylaldehyde (0.5 g, 2.49 mmol) and 4-
bromo-2-methyl-2-butene (0.45 g, 2.99 mmol) in anhydrous DMF 
(12 mL) were added finely ground K2CO3 (1.14 g, 8.22 mmol) and KI 
(0.03 g, 0.2 mmol). The reaction mixture was left to stir at room 
temperature under a nitrogen atmosphere for 3 hours. The reaction mixture was 
poured in to H2O and partitioned in Et2O. The aqueous phase was extracted with 
Et2O (3 ×15 mL). The organic extracts were combined, dried over Na2SO4, 
filtered and concentrated in vacuo. The crude product was purified by flash 
chromatography, eluting with 99:1 petroleum ether: EtOAc. 13: 0.6 g (yield 90 
%), yellow oil; 1H NMR (400 MHz, CDCl3) δ 1.72 (s, 3H), 1.76 (s, 3H), 4.57-4.59 
(m, 2H), 5.41-5.45 (m, 1H), 6.84-6.86 (m, 1H), 7.53-7.56 (m, 1H), 7.85-7.86 (m, 
1H), 10.35 (s, 1H).  
 
 
Domino-Knoevenagel Diels Alder reaction (K-DA) (intramolecular 
fashion) procedure (a) for the synthesis of (6aR,12bS)-11-bromo-2,4,6,6-
tetramethyl-6,6a,7,12b-tetrahydrochromeno[4',3':4,5]pyrano [2,3-
d]pyrimidine-1,3(2H,4H)-dione 15 
1,3-dimethylbarbituric acid 5c (0.15 g, 0.96mmol) was stirred 
with the 5-bromo-2-((3-methylbut-2-en-1-yl) oxy) 
benzaldehyde 13 (0.38 g,1.44 mmol) and ethylene diammoniun 
diacetate (0.03g, 0.19 mmol) in dichloromethane at room 
temperature for 24 hours. The reaction mixture evaporated to dryness and the 
crude product was purified on silica eluting with 7: 3 petroleum ether: EtOAc.  
15: 0.29 g (yield 74%), white powder; 1H NMR (CDCl3, 400 MHz) δ 1.14 (s, 
3H), 1.56 (s, 3H), 2.06-2.08 (m, 1H), 3.27 (s, 3H), 3.35-3.37 (m, 3H), 4.24-4.25 
(m, 1H), 4.32-4.41 (m, 2H), 6.51-6.53 (m, 1H), 7.08-7-11 (m, 1H), 7.47-7.48 (m, 
1H). 13C NMR (CDCl3, 100 MHz) δ 23.9, 28.2, 28.4, 28.9, 29.1, 38.7, 65.0, 84.0, 
88.0, 113.5, 117.7, 125.2, 130.9, 132.5, 151.2, 152.8, 155.7, 163.9, 198.1. 
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Domino-Knoevenagel Diels Alder reaction (K-DA) (intramolecular 
fashion) procedure (b) for the synthesis of (6aR,12bS)-11-bromo-2,4,6,6-
tetramethyl-6,6a,7,12b-tetrahydrochromeno[4',3':4,5]pyrano [2,3-
d]pyrimidine-1,3(2H,4H)-dione 15 
Into a 10 mL process vial equipped with a stirring bar were placed 
the aldehyde 13 (0.15 g, 0.56 mmol), 1,3-dimethylbarbituric acid 
5c (1.1 g, 0.73 mmol), ethylene diammonium diacetate (0.02 
equiv, 0.11 mmol) and ethanol. The vial was sealed and then 
irradiated via two consecutive synthetic steps. In the first one the reaction mixture 
was exposed for 10:00 minutes at 140° C under 100 W. In the second step, the 
same reaction was irradiated for 5 minutes at 160° C under 100 W. The reaction 
mixture evaporated to dryness and the crude product was purified on silica eluting 
with 7: 3 petroleum ether: EtOAc.  
15: 0.2 g (yield 88%), white powder; 1H NMR (CDCl3, 400 MHz) δ 1.14 (s, 3H), 
1.56 (s, 3H), 2.06-2.08 (m, 1H), 3.27 (s, 3H), 3.35-3.37 (m, 3H), 4.24-4.25 (m, 
1H), 4.32-4.41 (m, 2H), 6.51-6.53 (m, 1H), 7.08-7-11 (m, 1H), 7.47-7.48 (m, 1H). 
13C NMR (CDCl3, 100 MHz) δ 23.9, 28.2, 28.4, 28.9, 29.1, 38.7, 65.0, 84.0, 88.0, 
113.5, 117.7, 125.2, 130.9, 132.5, 151.2, 152.8, 155.7, 163.9, 198.1. 
 
 
Suzuki couplingreaction procedure (a) for the synthesis of(6aR,12bS)-11-(4-
hydroxyphenyl)-2,4,6,6-tetramethyl-6,6a,7,12b-
tetrahydrochromeno[4',3':4,5]pyrano[2,3-d]pyrimidine-1,3(2H,4H)-dione 16a 
This product was achieved following the general synthetic 
procedure described above for the Suzuki Coupling 
reaction, allowing to react 15 (0.2 g, 0.49 mmol) and the 
boronic acid 11d ( 0.135 g, 0.98 mmol). The crude product 
was purified by flash chromatography, eluting with 5: 5 petroleum ether: EtOAc.  
16a: 0.05 g (yield 24%), whitish powder; 1H NMR (400 MHz, DMSO-d6) δ 1.14 
(s, 3H), 1.54(s, 3H), 2.24-2.26 (m, 1H), 3.19 (s, 3H), 3.29 (s, 3H), 4.17-4.19 (m, 
1H), 4.32-4.35 (m, 1H), 4.41-4.45 (m, 1H), 6.67-6.69 (m, 1H), 6.75(d, J = 8.8 Hz, 
2H),7.21-7.24 (m, 1H), 7.27 (d, J = 8.8 Hz, 2H),7.57 (s, 1H), 9.35 (s, 1H). 13C 
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NMR (100 MHz, DMSO-d6) δ 23.6, 27.3, 27.9, 28.5, 28.6, 64.2, 83.5, 87.5, 115.6, 
115.7, 123.3, 125.2, 127.0, 127.8, 131.2, 132.2, 150.5, 152.5, 155.2, 156.3, 163.3. 
 
 
General parallel procedure for the Suzuki coupling procedure (b)  
 
A 10 mL process vial equipped with a stirring bar was charged with the 
bromine derivative 15 (1.0 equiv), the suitable boronic acid 11d-e (1.5 equiv), 
aqueous Na2CO3 (2M, 2.0 equiv) and a mixture of EtOH: H2O in 2:1 ratio. Each 
reaction mixture was deoxygenated with a stream of N2 for 10 min and then 
Pd(Ph3P)4 (0.05 equiv) was added. The vials was sealed and irradiated at 150° C 
for 10:00 min under 40W. Each reaction mixture was transferred into a separatory 
funnel and partitioned between 1N NaOH (15 mL) and EtOAc (15 mL). The 
organic phase was collected and the aqueous layer was extracted again with 
EtOAc (3 × 15 mL). The combined organic portions were washed with brine, 
dried over Na2SO4 and concentrated in vacuo. Each crude product was purified by 
flash chromatography. 
 
 
(6aR,12bS)-11-(4-hydroxyphenyl)-2,4,6,6-tetramethyl-6,6a,7,12b-
tetrahydrochromeno[4',3':4,5]pyrano[2,3-d]pyrimidine-1,3(2H,4H)-dione 16a 
This product was synthesized trough the general parallel 
procedure for the Suzuki coupling procedure (b), allowing 
to react the bromine derivative 15 (0.07 g, 0.17 mmol) with 
the (4-hydroxyphenyl)boronic acid 11d. The crude 
biphenyl derivative was purified on silica eluting with 6.0: 4.0 petroleum ether: 
EtOAc. 
15a: 0.13 g (yield 84%); whitish powder. 1H NMR (400 MHz, DMSO-d6) δ 1.14 
(s, 3H), 1.54 (s, 3H), 2.24-2.26 (m, 1H), 3.19 (s, 3H), 3.29 (s, 3H), 4.17-4.19 (m, 
1H), 4.32-4.35 (m, 1H), 4.41-4.45 (m, 1H), 6.67-6.69 (m, 1H), 6.75 (d, J = 8.8 Hz, 
2H), 7.21-7.24 (m, 1H), 7.27 (d, J = 8.8 Hz, 2H), 7.57 (s, 1H), 9.35 (s, 1H). 13C 
NMR (100 MHz, DMSO-d6) δ 23.6, 27.3, 27.9, 28.5, 28.6, 54.4, 64.2, 83.5, 87.5, 
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115.6, 115.7, 123.3, 125.2, 127.0, 127.8, 131.2, 132.2, 150.5, 152.5, 155.2, 156.3, 
163.3. 
 
(6aR,12bS)-11-(4-(hydroxymethyl)phenyl)-2,4,6,6-tetramethyl-6,6a,7,12b-
tetrahydrochromeno[4',3':4,5]pyrano[2,3-d]pyrimidine-1,3(2H,4H)-dione 16b 
This product was synthesized trough the general parallel 
procedure for the Suzuki coupling procedure (b), allowing 
to react the bromine derivative 15 (0.07 g, 0.17 mmol) 
with the (4-(hydroxymethyl)phenyl)boronic acid 11e. The 
crude biphenyl derivative was purified on silica eluting with 5.2: 4.8 petroleum 
ether: EtOAc.  
16b: 0.07 g (yield 95%); whitish powder. 1H NMR (400 MHz, CDCl3) δ 1.24 (s, 
3H), 1.61 (s, 3H), 1.80 (s br, 1H), 2.13-2.16 (m, 1H), 3.31 (s, 3H), 3.39 (s, 3H), 
4.36-4.39 (m, 1H), 4.41-4.49 (m, 2H), 4.68 (s, 2H), 6.75-6.77 (m, 1H), 7.30-7.33 
(m, 1H), 7.36 (d, J = 8 Hz, 2H), 7.50 (d, J = 8 Hz, 2H), 7.70 (s, 1H). 13C NMR 
(100 MHz, CDCl3) δ 24.1, 28.3, 28.5, 28.9, 29.3, 38.9, 65.1, 65.3, 84.1, 88.6, 
116.4, 123.3, 126.6, 126.9, 127.6, 128.7, 133.8, 139.3, 140.5, 151.3, 153.3, 155.6, 
164.2. 
 
 
4'-bromo-[1,1'-biphenyl]-4-ol 17147 
An oven-dried pressure tube was charged with 4-
methoxyphenylboronic acid (1.0 g, 6.6 mmol), 1,4-
dibromobenzene (2.3 g, 9.7 mmol), Pd(PPh3)4 (0.31 g, 0.3 
mmol), 10.0 mL of 2M Na2CO3 solution and 10.0 mL of toluene, and sealed under 
nitrogen. The contents were heated at 90-100 ºC for 14 hours. Subsequently, the 
tube was cooled and the organic matter was extracted with CHCl3. The combined 
extract was washed thoroughly with brine, dried over anhydrous Na2SO4, filtered 
and evaporated to yield the crude product, which was further purified by silica-gel 
column chromatography to afford pure 4-(4-bromophenyl)anisole (1.2 g, 69%).  
4-(4-Bromophenyl)anisole (1.2 g, 4.6 mmol), prepared above, was treated with 
BBr3(1.7 g, 6.9 mmol) in dry dichloromethane (30 mL) under ice-cold conditions. 
The reaction mixture was slowly allowed to attain room temperature and allowed 
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to stir for a period of 12 hours. Subsequently, the reaction mixture was poured 
into crushed ice and the organic contents were extracted with chloroform. The 
combined extract was washed thoroughly with brine, dried over anhydrous 
Na2SO4, filtered, and evaporated to yield the crude product. Further purification 
with silica-gel column chromatography, eluting with 9.3: 0.7 petroleum ether: 
EtOAc yielded pure 4-(4-bromophenyl)phenol. 
17: 1.1 g(yield 94%), colorless solid; 1H NMR (400 MHz, (CD3)2CO) δ 6.91 (d, 
J= 8.5 Hz, 2H), 7.50 (d, J= 8.5 Hz, 2H), 7.51-755 (m, 4H), 8.49 (s, 1H). 
 
 
4'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,1'-biphenyl]-4-ol 19 
4'-bromo-[1,1'-biphenyl]-4-ol 17 (0.15 g, 0.60 mmol), 
bis(pinacolato)diboron 18 (0.20 g, 0.78 mmol), KOAc 
(0.18 g, 1.80 mmol) and Pd(dppf)Cl2 (0.03g, 0.04 mmol) 
were suspended in dry DME (3 mL) in a 10 mL sealed 
glass tube. The sample was irradiated at 250 W, 150° C for 20 minutes. After 
completion of reaction, the vessel was cooled and the crude mixture was poured 
into H2O and extracted with EtOAc (3 × 15 mL). The organic phases were 
combined and the solvent was removed under reduced pressure. The resultant 
crude product was purified on silica eluting with 9: 1 petroleum ether: EtOAc.  
19: 0.16 g (yield 90%), white powder; 1H NMR (400 MHz, CDCl3) δ 1.35 (s, 
12H), 5.92 (s br, 1H), 6.88-6.92 (m, 2H), 7.47-7.50(m, 2H), 7.53 (d, J= 8 Hz, 2H), 
7.84 (d, J= 8 Hz, 2H). 
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(6aR,12bS)-11-(4'-hydroxy-[1,1'-biphenyl]-4-yl)-2,4,6,6-tetramethyl 
6,6a,7,12b-tetrahydrochromeno[4',3':4,5]pyrano[2,3-d]pyrimidine-
1,3(2H,4H)-dione 16c 
15 (0.10 g, 0.25 mmol), 4'-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-[1,1'-biphenyl]-4-ol 19 (0.11 g, 
0.38 mmol), Na2CO3 2M (0.25mL, 0.50 mmol) and 
PdCl2(PPh3)2 (0.09 g, 0.02 mmol) were suspended in 
a mixture of 2: 1 EtOH: H2O (3 mL) in a 10 mL sealed glass tube. The sample 
was deoxygenated with a stream of N2 for 10 min and it was irradiated at 150 W, 
120° C for 30 minutes. After completion of reaction, the vessel was cooled and 
the crude mixture was poured into H2O and extracted with EtOAc (3 × 15 mL). 
The organic phases were combined and the solvent was removed under reduced 
pressure. The resultant crude product was purified on silica eluting with 5: 5 
petroleum ether: EtOAc.  
16c: 0.05 g (yield 40%), white powder; 1H NMR (400 MHz, DMSO-d6) δ 1.16 (s, 
3H), 1.55 (s, 3H), 2.27-2.30 (m,1H), 3.19 (s,3H), 3.21 (s, 3H), 4.20-4.22 (m, 1H), 
4.35 (dd, J = 4, 12 Hz, 1H), 4.46(dd, J = 4, 12 Hz, 1H), 6.74-6.76 (m, 1H), 6.79-
6.83 (m, 2H), 7.36-7.39 (m, 1H), 7.45-7.52 (m, 4H), 7.57-7.60 (m,2H), 7.73 (s, 
1H), 9.52 (s br, 1H). 13C NMR (100 MHz, DMSO-d6) δ 23.6, 26.8, 27.3, 27.9, 
28.6, 37.3, 54.6, 64.4, 83.5, 87.5, 115.8, 116, 123.5, 125.7, 126.3, 127.5, 128.5, 
130.4, 131.6, 138.2, 138.3, 150.5, 153.3, 155.2, 157.1, 163.4. 
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5.2 Minimally Structured hERG Blockers 
General Synthetic Procedure for selective n-alkylation of substituted 
amines under microwave irradiation. 
 
In a 10 mL process vial equipped with a stirring bar, to a solution of 1-chloro3-
phenylpropane (1 equiv) in anhydrous Dimethylformamide was added the 
appropriate amines 28-34 (3 equiv), K2CO3 (1 equiv) and KI (1 equiv). The 
reaction mixture was irradiated for 10 minutes to 110° C at 150 W. To the cooled 
mixture was added NaHCO3 saturated solution and the organic phase was 
extracted with Et2O (3 ×15mL). The organic layers were collected, dried over 
anhydrous Na2SO4 and evaporated under vacuum. The crude product was purified 
by flash chromatography. All the compounds were converted into their 
hydrochloride salts. The NMR spectra recorded in CD3OD are referred to 
hydrochloride forms. 
 
 
N1-(4-fluorophenyl)-N1-phenyl-N2-(3-phenylpropyl)ethane-1,2-diamine 36 
1-chloro-3-phenylpropane 35 (0.05 g, 0.32 mmol) was allowed 
to react with amine 28 according to the general synthetic 
procedure for selective n-alkylation described above. The crude 
product was purified by flash chromatography eluting with 6.5: 
3.5 petroleum ether: EtOAc.  
36:0.07g (yield 60 %), brown oil; 1H NMR (400 MHz, CDCl3) 
δ 1.40 (s br, 1H), 1.73-1.80 (m, 2H), 2.59-2.63 (m, 4H), 2.84 (t, J= 6.8 Hz, 2H), 
3.78 (t, J= 6.8 Hz, 2H), 6.83-6.87 (m, 3H), 6.95-7.05 (m, 4H), 7.14-7.27 (m, 7H). 
13C NMR (100 MHz, CDCl3) δ 31.8, 33.7, 47.3, 49.6, 52.6, 116.2, 116.4, 118.6, 
120.2, 125.2, 125.3, 125.9, 128.5, 129.4, 142.1, 144.2, 144.2, 148.6, 157.8, 160.2. 
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N1,N1-bis(4-chlorophenyl)-N2-(3-phenylpropyl)ethane-1,2-diamine 37 
1-chloro-3-phenylpropane 35 (0.04 g, 0.27 mmol) was 
allowed to react with amine 29 according to the general 
synthetic procedure for selective n-alkylation described 
above. The crude product was purified by flash 
chromatography eluting with 7: 3 petroleum ether: EtOAc. 
37: 0.05 g (yield 50 %), yellow oil; 1H NMR (400 MHz, 
CDCl3) δ 1.73-1.80 (m, 2H), 2.59-2.62 (m, 4H), 2.81 (t, J= 6.8 Hz, 2H), 3.76 (t, 
J= 6.8 Hz, 2H), 6.89-6.93 (m, 4H), 7.12-7.27 (m, 9H). 13C NMR (100 MHz, 
CDCl3) δ 31.8, 33.7, 47.1, 49.5, 52.6, 122.4, 126.0, 126.9, 128.4, 128.5, 129.5, 
142.1, 146.4. 
 
 
N1-(4-chlorophenyl)-N1-phenyl-N2-(3-phenylpropyl)ethane-1,2-diamine 38 
1-chloro-3-phenylpropane 35 (0.06 g, 0.38 mmol) was allowed 
to react with amine 30 according to the general synthetic 
procedure for selective n-alkylation described above. The 
crude product was purified by flash chromatography eluting 
with 7.5: 2.5 petroleum ether: EtOAc.  
38: 0.09 g (yield 65 %), yellow oil; 1H NMR (400 MHz, 
CDCl3) δ 1.73-1.81 (m, 2H), 1.84 (s br, 1H), 2.58-2.63 (m, 4H), 2.84 (t, J= 6.8 
Hz, 2H), 3.81 (t, J= 6.8 Hz, 2H), 6.88 (d, J= 8.4 Hz, 2H), 6.97-7.03 (m, 3H), 7.12-
7.18 (m, 5H), 7.23-7.29 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 31.7, 33.7, 47.2, 
49.5, 52.4, 121.4, 122.2, 122.5, 125.9, 126.0, 128.5, 129.3, 129.6,142.1, 146.9, 
147.7. 
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N1,N1-bis(4-methoxyphenyl)-N2-(3-phenylpropyl)ethane-1,2-diamine 39 
1-chloro-3-phenylpropane 35 (0.04 g, 0.27 mmol) was 
allowed to react with amine 31 according to the general 
synthetic procedure for selective n-alkylation described 
above. The crude product was purified by flash 
chromatography eluting with 6: 4 petroleum ether: EtOAc. 
39: 0.08 g (yield 76 %), black-brown oil; 1H NMR (400 
MHz, CDCl3) δ 1.94-1.98 (m, 2H), 2.67 (t, J= 6.4 Hz, 2H), 3.00-3.03 (m, 2H), 
3.17 (t, J= 6.4 Hz, 2H), 3.73 (s, 6H), 3.86-3.88 (m, 2H), 6.83-6.86 (m, 4H), 6.89-
6.91 (m, 4H), 7.16-7.19 (m, 3H), 7.25-7.28 (m, 2H). 13C NMR (100 MHz, 
CD3OD) δ 28.9, 33.5, 46.3, 50.3, 56.0, 115.8, 124.0, 127.5, 129.4, 129.7, 141.5, 
143.2, 157.0. 
 
 
N1-(4-methoxyphenyl)-N1-phenyl-N2-(3-phenylpropyl)ethane-1,2-diamine 40 
1-chloro-3-phenylpropane 35 (0.07 g, 0.45 mmol) was 
allowed to react with amine 32 according to the general 
synthetic procedure for selective n-alkylation described 
above. The crude product was purified by flash 
chromatography eluting with 7: 3 petroleum ether: EtOAc. 
40: 0.11 g (yield 70 %), black-brown oil;1H NMR(400 MHz, 
CDCl3) δ 1.94-1.98 (m, 2H), 2.67 (t, J=7.6 Hz, 2H), 3.00-3.04(m, 2H), 3.21 (t, 
J=6.8 Hz, 2H), 3.78 (s, 3H), 3.93 (t, J=6.8 Hz, 2H), 6.75-6.82 (m, 3H), 6.94 (d, 
J=8 Hz, 2H), 7.08 (d, J= 8 Hz, 2H), 7.15-7.19 (m, 5H), 7.25-7.29 (m, 2H). 13C 
NMR (100 MHz, CDCl3)δ 31.6, 33.7, 47.3, 49.4, 52.2, 55.6, 104.3, 115.1, 116.2, 
118.6, 126.0, 127.3, 128.5, 129.2, 140.7, 142.1, 149.3, 156.7. 
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N1,N1-bis(4-fluorophenyl)-N3-(3-phenylpropyl)propane-1,3-diamine 41 
1-chloro-3-phenylpropane 35 (0.03 g, 0.19 mmol) was 
allowed to react with amine 33 according to the general 
synthetic procedure for selective n-alkylation described 
above. The crude product was purified by flash 
chromatography eluting with 6: 4 petroleum ether: EtOAc. 
41: 0.05 g (yield 75 %), yellowish-brown oil; 1H NMR(400 
MHz, CD3OD) δ1.91-1.99 (m, 4H), 2.68 (t, J= 7.6, 2H), 2.95 (t, J= 8, 2H), 3.05 (t, 
J= 8, 2H), 3.72 (t, J= 7.6, 2H), 6.93-7.03 (m, 8H), 7.16-7.19 (m, 3H), 7.25-7.29 
(m, 2H). 13C NMR(100 MHz, CD3OD) δ 25.6, 29.0, 33.5, 46.8, 48.6, 50.7, 116.9, 
117.0, 123,9 124.0, 127.4, 129.4, 129.7, 141.5, 145.8, 145.9, 158.5, 160.9.  
 
 
N1-(4-fluorophenyl)-N1-phenyl-N3-(3-phenylpropyl)propane-1,3-diamine 42 
1-chloro-3-phenylpropane 35 (0.03 g, 0.19 mmol) was 
allowed to react with amine 34 according to the general 
synthetic procedure for selective n-alkylation described 
above. The crude product was purified by flash 
chromatography eluting with 5.5: 4.5 petroleum ether: 
EtOAc.  
42: 0.06 g (yield 80 %), yellowish-brown oil; 1H NMR(400 MHz, CDCl3) δ1.75-
1.82 (m, 4H), 2.60 (t, J= 7.2, 2H), 2.62-2.66 (m, 4H), 3.70 (t, J= 7.2, 2H), 6.82-
6.85 (m, 3H), 6.95-7.04 (m, 4H), 7.15-7.21 (m, 5H), 7.25-7.28 (m, 2H). 13C 
NMR(100 MHz, CDCl3)δ 28.2, 31.9, 33.8, 47.6, 49.7, 50.6, 116.1, 116.3, 118.4, 
119.9, 125.2, 125.3, 125.9, 128.4, 129.3, 142.3, 144.1, 144.2, 148.6, 160.1. 
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General Procedure of an improvement of Buchwald-Hartwig cross-
coupling for the synthesis of diphenylamines 
In a pressure tube under inert atmosphere, the appropriate substituted 
phenylamines 63 and 64 (1.25 equiv), DPPF (0.15 equiv), (DPPF)PdCl2·CH2Cl2 
(0.05 equiv) and sodium tert-butoxide (1.25 equiv) were added to proper 
iodobenzene derivatives 65-67 (1 equiv) in dried Tetrahydrofuran. The reaction 
mixturewas heated at 100 °C for 3 hours and then cooled to room temperature. 
HCl 1M was added; the mixture wasbasified with NaHCO3to pH 9 and extracted 
with EtOAc (3 ×15 mL); and the combined organic layer was dried over Na2SO4 
and concentrated. The residue was purified by flashcolumn chromatography. 
 
 
4-fluoro-N-phenylaniline 43 
This product was prepared according to the reported general 
procedure from the iodobenzene 65 (1 g, 4.90 mmol) and the 4-
fluorophenylamine 63. The crude product was purified by flash chromatography 
eluting with petroleum ether.  
43:1.7 g (yield 91 %), yellowish-brown oil; 1H NMR(400 MHz, CDCl3)δ5.56 (s 
br, 1H), 6.91 (t, J=7.2 Hz, 1H), 6.96-7.06 (m, 6H), 7.23-7.27 (m, 2H). 
 
 
bis(4-chlorophenyl)amine 44 
This product was prepared according to the reported general 
procedure from the 1-chloro-4-iodobenzene67 (0.25 g, 1.05 
mmol) and the 4-chlorophenylamine 64. The crude product was purified by flash 
chromatography eluting with 9.8: 0.2 petroleum ether: EtOAc.  
44:0.2 g (yield 80 %), yellowoil; 1H NMR (400 MHz, CDCl3) δ 5.62 (s br, 1H), 
6.93-6.96 (m, 4H), 7.19-7.22 (m, 4H). 
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4-chloro-N-phenylaniline45 
This product was prepared according to the reported general 
procedure from the iodobenzene 65 (0.5 g, 2.46 mmol) and the 
4-chlorophenylamine 64. The crude product was purified by flash 
chromatography eluting with 9.8: 0.2 petroleum ether: EtOAc. 
45:0.4 g (yield 70 %), brown oil; 1H NMR (400 MHz, CDCl3) δ 5.65 (s br, 1H), 
6.93-6.99 (m, 3H), 7.02-7.05 (m, 2H), 7.18-7.21 (m, 2H), 7.25-7.29 (m, 2H). 
 
 
bis(4-fluorophenyl)amine 48 
This product was prepared according to the reported general 
procedure from the 1-fluoro-4-iodobenzene 66 (0.5 g, 2.25 
mmol) and the 4-fluorophenylamine 63. The crude product was purified by flash 
chromatography eluting with petroleum ether.  
48: 0.38 g (yield 82 %), yellowish-brown oil; 1H NMR (400 MHz, CDCl3) δ 5.42 
(s br, 1H), 6.94-6.98 (m, 4H), 7.19-7.22 (m, 4H). 
 
 
General Procedure for n-alkylation of Diphenylamines (route b). 
A solution of the appropriate diphenylamines 43-48 (1 equiv), in 20 mL of 
anhydrous Et2O under nitrogen atmosphere, was treated with 2.5 M n-BuLi (1.5 
equiv) in hexane at -78° C. After the reaction mixture had stirred for 30 minutes at 
room temperature, a solution of 2-chloroethyltosylate (1.3equiv) in 6 mL of 
anhydrous Et2O was added. The reaction was stirred for 18 hours and after this 
time water was added. The organic phase was extracted with Et2O (3 × 15 mL) 
and the collected organic layers were dried over anhydrous Na2SO4 and 
concentrated. The crude product was chromatographed on a silica gel column. 
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N-(2-chloroethyl)-4-fluoro-N-phenylaniline 49 
49 was prepared as previously described starting from the 
diphenylamine 43 (0.3 g, 1.60 mmol). The crude product was 
used in the next synthetic step without further purification.  
49: 1H NMR (400 MHz, CDCl3) δ 3.65 (t, J=7.2 Hz, 2H), 3.99 (t, J=7.2 Hz, 2H), 
6.83-6.89 (m, 2H), 6.97-7.05 (m, 1H), 7.14-7.16 (m, 2H), 7.20-7.29 (m, 4H). 
 
 
4-chloro-N-(2-chloroethyl)-N-(4-chlorophenyl)aniline 50 
50 was prepared as previously described starting from the 
diphenylamine 44 (0.25 g, 1.05 mmol). The crude product was 
used in the next synthetic step without further purification. 
50: 1H NMR (400 MHz, CDCl3) δ 3.62 (t, J= 7.2 Hz, 2H), 3.97 (t, J= 7.2 Hz, 2H), 
6.88-7.13 (m, 4H), 7.14-7.23 (m, 4H). 
 
 
4-chloro-N-(2-chloroethyl)-N-phenylaniline 51 
51 was prepared as previously described starting from the 
diphenylamine 45 (0.25 g, 1.23 mmol). The crude product was 
used in the next synthetic step without further purification.  
51: 1H NMR (400, MHz, CDCl3) δ 3.64 (t, J= 7.2 Hz, 2H), 4.00 (t, J= 7.2 Hz, 
2H), 6.86-6.90 (m, 2H), 6.99-7.05 (m, 2H), 7.18-7.22 (m, 1H), 7.24-7.44 (m, 4H). 
 
 
N-(2-chloroethyl)-4-methoxy-N-(4-methoxyphenyl)aniline 52 
52 was prepared as previously described starting from the 
diphenylamine 46 (0.25 g, 1.09 mmol). The crude 
product was used in the next synthetic step without 
further purification.  
52: 1H NMR (400, MHz, CDCl3) δ 3.70 (s, 6H), 3.75 (t, J= 7.2 Hz,2H), 4.17 (t, J= 
7.2 Hz, 2H), 7.03-7.09(m, 4H), 7.12-7.21 (m, 4H). 
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N-(2-chloroethyl)-4-methoxy-N-phenylaniline 53 
53 was prepared as previously described starting from the 
diphenylamine 46 (0.25 g, 1.09 mmol). The crude product was 
used in the next synthetic step without further purification.  
53: 1H NMR (400, MHz, CDCl3) δ 3.68 (s, 3H), 3.73 (t, J= 7.2 Hz,2H), 4.15 (t, J= 
7.2 Hz, 2H), 7.01-7.08 (m, 2H), 7.12-7.19 (m, 2H), 7.20-7.22 (m, 1H), 7.25-7.44 
(m, 4H).  
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General Procedure for Microwave assisted n-alkylation of Diphenylamines 
(route c). 
A solution of the proper diphenylamines 43 and 48 (1 equiv) in anhydrous 
Tetrahydrofuran 12 mL was treated with NaH (5 equiv) and exposed to MW 
irradiation at 200 W, 140° C for 40 minutes. The sample was cooled to room 
temperature and then 1-bromo-3-chloropropane (2 equiv) was added. The reaction 
mixture was irradiated at 200 W, 120° C for 21 minutes. Water was added and the 
organic layers was extracted with Et2O (3 × 15 mL). The collected organic phases 
were dried over anhydrous Na2SO4 and concentrated. The crude product was 
purified by flash chromatography. 
 
 
N-(3-chloropropyl)-4-fluoro-N-(4-fluorophenyl)aniline 54 
The diphenylamines 43 (0.5 g, 2.44 mmol) was allowed to react 
according to the described general procedure reported above. 
The crude product was purified by flash chromatography 
eluting with petroleum ether.  
54: 0.2 g (yield 30 %), yellowish-brown oil; 1H NMR (400 MHz, CDCl3) δ 2.04-
2.08 (m, 2H), 3.60 (t, J= 6.8, 2H), 3.79 (t, J= 6.8, 2H), 6.88-6.97 (m, 8H). 
 
 
N-(3-chloropropyl)-4-fluoro-N-phenylaniline 55 
The diphenylamines 48 (0.3 g, 1.60 mmol) was allowed to react 
according to the described general procedure reported above. 
The crude product was purified by flash chromatography eluting 
with petroleum ether.  
55: 0.11 g (yield 27 %), yellowish-brown oil; 1H NMR (400 MHz, CDCl3) δ 2.08-
2.12 (m, 2H), 3.61 (t, J= 6.8, 2H), 3.84 (t, J= 6.8, 2H), 6.86-6.89 (m, 3H), 6.97-
7.04 (m, 4H), 7.20-7.23 (m, 2H). 
  
N
F F
Cl
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General Procedure of Gabriel Synthesis for the Preparation of N1-
diphenyl-N2-alkylamines.  
The Gabriel Synthesis proceeded through two reaction steps. In the first one a 
solution of the appropriate N-diphenylalkylchlorides 49-55 (1 equiv) and 
potassium phthalimide (1.5 equiv) in 4 mL of dry Dimethylformamide was heated 
under reflux for 6-9 hours. The reaction mixture was diluted with water and 
extracted with (4 × 15 mL) of Et2O. The combined organic layers were washed 
with water, dried over Na2SO4, and evaporated. The crude product was purified 
by flash chromatography to give the corresponding N-alkylphatalimide 
derivatives 56-62. 
In the second step a solution of the proper N-alkylphatalimide derivatives 56-
62 (1 equiv) and hydrazine hydrate 50-60 % (7.5 equiv) was heated to reflux for 3 
hours. After the solution was cooled the solvent was evaporated and the residue 
was chromatographed on a silica gel column to give the corresponding N1-
diphenyl-N2-alkylamines 28-34. 
 
 
2-(2-((4-fluorophenyl)(phenyl)amino)ethyl)isoindoline-1,3-dione 56 
56 has been obtained according to the general procedure 
described for the first step of Gabriel Synthesis, starting from 49 
(0.4 g, 1.64 mmol). The crude product was purified by flash 
chromatography eluting with 9.9: 0.1 petroleum ether: EtOAc. 
56: 0.45 g (yield 76 %), orange solid; 1H NMR (400 MHz, 
CDCl3) δ 3.97 (s, 4H), 6.80-6.83 (m, 1H), 6.91-6.97 (m, 4H), 7.05-7.09 (m, 2H), 
7.16-7.20 (m, 2H), 7.67-7.70 (m, 2H), 7.78-7.80 (m, 2H). 
 
  
N
F
N OO
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N1-(4-fluorophenyl)-N1-phenylethane-1,2-diamine 28 
28 was prepared following the general procedure described for 
the second step of Gabriel Synthesis, starting from 56 (0.4 g, 1.11 
mmol). The crude product was purified by flash chromatography 
eluting with 9.7: 0.3 CH2Cl2: MeOH, using saturated silica gel with 50 % of 
ammonia. 
28: 0.23 g (yield 90 %), yellow oil; 1H NMR (400 MHz, CDCl3) δ 1.29 (s br, 1H), 
2.93 (t, J=6.4 Hz, 2H), 3.74 (t, J=6.4 Hz, 2H), 6.86-6.88 (m, 3H), 6.96-7.06 (m, 
4H), 7.19-7.24 (m, 2H). 
 
 
2-(2-(bis(4-chlorophenyl)amino)ethyl)isoindoline-1,3-dione 57 
57 has been obtained according to the general procedure 
described for the first step of Gabriel Synthesis, starting from 
50 (0.46 g, 1.53 mmol). The crude product was purified by 
flash chromatography eluting with 9.8: 0.2 petroleum ether: 
EtOAc. 
57: 0.52 g (yield 82 %), orange solid; 1H NMR (400 MHz, CDCl3) δ 3.93-3.97 
(m, 4H), 6.93-7.13 (m, 4H), 7.14-7.16 (m, 4H), 7.68-7.62 (m, 2H), 7.76-7.79 (m, 
2H). 
 
 
N1,N1-bis(4-chlorophenyl)ethane-1,2-diamine 29 
29 was prepared following the general procedure described 
for the second step of Gabriel Synthesis, starting from 57 
(0.37 g, 0.90 mmol). The crude product was purified by flash 
chromatography eluting with 8.2: 1.8 CH2Cl2: MeOH, using saturated silica gel 
with 50 % of ammonia. 
29:0.23 g (yield 91 %), yellow oil; 1H NMR (400 MHz, CDCl3) δ 1.53 (s br, 1H), 
2.94 (t, J=6.4 Hz, 2H), 3.74 (t, J=6.4 Hz, 2H), 6.92-6.95 (m, 4H), 7.19-7.22 (m, 
4H). 
 
  
N
Cl Cl
N OO
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2-(2-((4-chlorophenyl)(phenyl)amino)ethyl)isoindoline-1,3-dione 58 
58 has been obtained according to the general procedure 
described for the first step of Gabriel Synthesis, starting from 51 
(0.56 g, 2.10 mmol). The crude product was purified by flash 
chromatography eluting with 9.3: 0.7 petroleum ether: EtOAc. 
58: 0.55 g (yield 70 %), orange solid; 1H NMR (400 MHz, 
CDCl3) δ 3.94-4.01 (m, 4H), 6.91-6.96 (m, 3H), 7.04-7.06 (m, 2H), 7.13-7.15 (m, 
2H), 7.21-7.25(m, 2H), 7.67-7.70 (m, 2H), 7.77-7.79 (m, 2H). 
 
 
N1-(4-chlorophenyl)-N1-phenylethane-1,2-diamine 30 
30was prepared following the general procedure described for 
the second step of Gabriel Synthesis, starting from 58 (0.46 g, 
1.22 mmol). The crude product was purified by flash 
chromatography eluting with 9.8: 0.2 CH2Cl2: MeOH, using saturated silica gel 
with 50 % of ammonia. 
30:0.28 g (yield 93 %), yellow oil; 1H NMR(400 MHz, CDCl3)δ1.43 (s br, 2H), 
2.94 (t, J=6.4 Hz, 2H), 3.76 (t, J=6.4 Hz, 2H), 6.87-6.91 (m, 2H), 6.97-7.03 (m, 
3H), 7.15-7.19 (m, 2H), 7.24-29 (m, 2H). 
 
 
2-(2-(bis(4-methoxyphenyl)amino)ethyl)isoindoline-1,3-dione 59 
59 has been obtained according to the general procedure 
described for the first step of Gabriel Synthesis, starting 
from 52 (0.43 g, 1.47 mmol). The crude product was 
purified by flash chromatography eluting with 8.6: 1.4 
petroleum ether: EtOAc. 
59: 0.37 g (yield 62 %), yellow solid; 1H NMR (400 MHz, CDCl3) δ 3.73 (s, 6H), 
3.92-3.93(m, 4H), 6.77 (d, J=4.9 Hz, 4H), 6.93 (d, J=4.9 Hz, 4H),7.74-7.76 (m, 
2H), 7.85-7.86 (m, 2H). 
 
  
N
H3CO OCH3
N OO
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N1,N1-bis(4-methoxyphenyl)ethane-1,2-diamine 31 
31 was prepared following the general procedure 
described for the second step of Gabriel Synthesis, 
starting from 59 (0.45 g, 1.12 mmol). The crude product 
was purified by flash chromatography eluting with 9.7: 0.3 CH2Cl2: MeOH, using 
saturated silica gel with 50 % of ammonia. 
31: 0.23 g (yield 74 %), brown oil; 1H NMR (400 MHz, CDCl3) δ 1.35 (s br, 2H), 
2.89 (t, J=6.4 Hz, 2H), 3.66 (t, J=6.4 Hz, 2H), 3.76 (s, 6H), 6.78-6.82(m, 4H), 
6.87-6.92 (m, 4H). 
 
 
2-(2-((4-methoxyphenyl)(phenyl)amino)ethyl)isoindoline-1,3-dione 60 
60 has been obtained according to the general procedure 
described for the first step of Gabriel Synthesis, starting from 
53 (0.4 g, 1.53 mmol). The crude product was purified by 
flash chromatography eluting with 9.2: 0.8 petroleum ether: 
EtOAc. 
60: 0.35 g (yield 65 %), green-grey solid; 1H NMR (400 MHz, CDCl3) δ 3.76-
3.96 (m, 4H), 6.72-6.74 (m, 1H), 6.82-6.85 (m, 4H), 7.09-7.17 (m, 4H), 7.67-7.69 
(m, 2H), 7.78-7.80 (m, 2H). 
 
 
N1-(4-methoxyphenyl)-N1-phenylethane-1,2-diamine 32 
32 was prepared following the general procedure described for 
the second step of Gabriel Synthesis, starting from 60 (0.49 g, 
1.32 mmol). The crude product was purified by flash 
chromatography eluting with 9.8: 0.2 CH2Cl2: MeOH, using saturated silica gel 
with 50 % of ammonia. 
32: 0.22 g (yield 69 %), brown oil; 1H NMR (400 MHz, CDCl3) δ 1.32 (s broad, 
2H), 2.93 (t, J=6.4 Hz, 2H), 3.71 (t, J=6.4 Hz, 2H), 3.80 (s, 3H), 6.75-6.77 (m, 
3H), 6.75-6.80 (m, 2H), 7.03-7.11 (m, 2H), 7.14-7.18(m, 2H). 
  
N
H3CO
NH2
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2-(3-(bis(4-fluorophenyl)amino)propyl)isoindoline-1,3-dione 61 
61 has been obtained according to the general procedure 
described for the first step of Gabriel Synthesis, starting 
from 54 (0.4 g, 1.42 mmol). The crude product was purified 
by flash chromatography eluting with 9.3: 0.7 petroleum 
ether: EtOAc. 
61: 0.31 g (yield 55 %), pink solid; 1H NMR (400 MHz, CDCl3) δ 1.95-2.02 (m, 
2H), 3.64-3.74 (m, 4H), 6.83-6.93 (m, 8H), 7.68-7.70 (m, 2H), 7.80-7.82 (m, 2H). 
 
 
N1,N1-bis(4-fluorophenyl)propane-1,3-diamine 33 
33 was prepared following the general procedure described for 
the second step of Gabriel Synthesis, starting from 61 (0.25 g, 
0.64 mmol). The crude product was purified by flash 
chromatography eluting with 9.8: 0.2 CH2Cl2: MeOH, using 
saturated silica gel with 50 % of ammonia. 
33:0.15 g (yield 89 %), brown oil; 1H NMR (400 MHz, CDCl3) δ 1.50 (s broad, 
2H), 1.73-1.79 (m, 2H) 2.74 (t, J=6.4 Hz, 2H), 3.69 (t, J=6.4 Hz, 2H), 6.72-6.99 
(m, 4H), 7.01-7.21 (m,4H). 
 
 
2-(3-((4-fluorophenyl)(phenyl)amino)propyl)isoindoline-1,3-dione 62 
62 has been obtained according to the general procedure 
described for the first step of Gabriel Synthesis, starting 
from 55 (0.39 g, 1.47 mmol). The crude product was 
purified by flash chromatography eluting with 9.3: 0.7 
petroleum ether: EtOAc. 
62: 0.27 g (yield 50 %), pink solid; 1H NMR (400 MHz, CDCl3) δ 1.98-2.05 (m, 
2H), 3.69-3.75 (m, 4H), 6.78-6.84 (m, 3H), 6.93-7.02 (m, 4H), 7.15-7.67 (m, 2H), 
7.68-7.71 (m, 2H), 7.79-7.82 (m, 2H). 
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N1-(4-fluorophenyl)-N1-phenylpropane-1,3-diamine 34 
34 was prepared following the general procedure described for 
the second step of Gabriel Synthesis, starting from 62 (0.23 g, 
0.61 mmol). The crude product was purified by flash 
chromatography eluting with 9.5: 0.5 CH2Cl2: MeOH, using 
saturated silica gel with 50 % of ammonia. 
34: 0.13 g (yield 85 %), brown oil; 1H NMR (400 MHz, CDCl3) δ 1.61 (s broad, 
2H), 1.73-1.81 (m, 2H) 2.77 (t, J=6.4 Hz, 2H), 3.72 (t, J=6.4 Hz, 2H), 6.82-6.85 
(m, 3H), 6.95-7.03 (m,4H), 7.17-7.21 (m, 2H). 
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5.3  Detailed biological methods 
 
5.3.1 Antiproliferative Activity Evaluation 
 
Cells 
K562 human myeloid cell line was used in this study. K562 is a cell line  
expressing the anti -apoptotic oncogene Bcr-Abl. 
 
Cell cultures  
Continuous neoplastic cells were grown in RPMI 1640 (Gibco Grand Island, 
NY, USA) containing 10% FCS (Gibco), 100 U/ml penicillin (Gibco), 100 µg/ml 
streptomycin (Gibco), and 2mM L-glutamine (Sigma Chemical Co, St Louis, 
MO) in a 5% CO2 atmosphere at 37 °C.  
 
Samples preparation  
Each compound was dissolved in dimethylsulphoxide (DMSO) in a stock 
solution at a concentration of 20 mM, stored at -20 °C and protected from light.  
In each experiment DMSO never exceeded 0.2% and this percentage did not 
interfere with cell growth.  
 
Cytotoxicity assays  
To evaluate the number of live and dead neoplastic cells, the cells were stained  
with trypan blue and counted on a hemocytometer. To determine the growth 
inhibitory activity of the compounds tested, 2 ×105cells were plated into 25 mm 
wells (Costar, Cambridge, UK) in 1 mL of complete medium and treated with 
different concentrations of each compound. After 48h of incubation, the number 
of viable cells was determined and expressed as percent of control proliferation. 
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5.3.2 hERG Blocking Capability Evaluation 
 
Patch clamp experiments  
The biological activity of compounds was determined by measuring inhibition of 
hERG currents using the whole-cell configuration of the patch-clamp technique in 
stably transfected HEK cells. 
Cells were superfused with room temperature extracellular Tyrode containing (in 
mM), NaCl 140, MgCl21, KCl 4, Glucose 10, HEPES 5, CaCl22, pH 7.4. Stock 
solutions of the compounds (in DMSO) were diluted in Tyrode to the desired 
concentrations. Total DMSO was < 0.1%.  
Borosilicate glass pipettes (Harvard Apparatus) with final resistances of 2 to 4 
MΩ were filled with an intracellular solution containing (in mM), KCl 130, Mg 
ATP 5, HEPES 10, pH 7.2. Cells were voltage clamped at a holding potential of -
80 mV and hERG currents activated with repetitive application of 5-s pulses to 0 
mV followed by a repolarising pulse to -50 mV to elicit tail currents.  
Peak tail current amplitudes following steady-state inhibition were measured, leak 
current subtracted, normalized to current in control Tyrodeand the resulting 
concentration-response relationships from individual cells fitted with a Hill 
function to obtain IC50and slope values.  
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 6.   Synthesis of Berberine metabolites 
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As underlying into introduction, the natural products have long been 
recognized as privileged scaffolds,157 due to their capability to interact specifically 
with biological macromolecules, especially proteins.158,159 Full characterization of 
biological and physico-chemical properties of natural compounds results often 
difficult to achieve, nevertheless their important roles as chemical probes,160,161 or 
as starting points for libraries synthesis,59,66 make them invaluable tools both in 
rational design of new chemical entities and in drug discovery pipeline. In this 
context, in my research group, we started a project in collaboration with the group 
of Prof. Roda aimed at investigating either the main physicochemical properties 
and plasma levels of Berberine 68 and its main metabolites: Berberrubine 69, 
Thalifendine 70, Demethyleneberberine 71, Jatrorrhizine 72 (Figure37). 
Berberine is a natural product endowed with several biological properties such as: 
antifungal,162 antiinflammation,163 antimalarial,164 cholesterol-lowering effect,165 
antihyperglycemia,166 immunoregulation,167 antitumor,168 anti-HIV activities.169 
 
 
Figure 37. Chemical Structures of Berberine and its main metabolites. 
One of its main metabolites, Berberrubine (69), showed to maintain some of the 
pharmacological properties exhibited by Berberine, such as anticancer activity,168 
up regulation for LDLR and mRNA expression.170 Furthermore, Berberrubine 
presents a particular chemical behaviour, that could assume an important role in 
determining its plasma concentration and absorption through biological 
compartments. It was supposed that 69 is able to tautomerize to highly conjugated 
and electroneutral quinoid structure 69a,171,172 more lipophilic than Berberine, and 
to give a resonance process with its zwitterionic form 69b171,172 (Figure 38). 
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Figure 38. Three possible forms of Berberrubine: enol 69, quinoid 69a, zwitterionic 69b 
forms. 
 
In this project, I prepared Berberrubine 69 and Demethyleneberberine 71 with 
the purpose to use them as internal standards for determining plasma levels of 
Berberine and its main metabolites through a sensitive HPLC-ESI-MS/MS 
method developed and validated by the research group of Prof. Roda. 
Furthermore, the same group performed the physicochemical properties 
characterization.173 
Moreover in order to demonstrate the presence of keto-enolic equilibrium, the 
enol 69 and quinoid 69a forms were synthesized and characterized and 1H-NMR 
analysis on a sample consisting of equimolar mixture of both forms was 
performed (See experimental section reported below). The spectrum displayed 
only one average set of signals demonstrating the existence of fast equilibration 
between this two tautomeric forms. Finally to further validate the above described 
equilibrium we carried out a 1H-15N HMQC correlation analysis for both 
structures. (See experimental section reported below). Regarding the equilibrium 
involving quinoid 69a and zwitterionic 69b forms, we suggested a quinoid-
zwitterion resonance in agreement with Suau et al.174 that proposed an analogue 
betaine-quinoid resonance for the protoberberine alkaloid 7,8-dehydrocaseamine. 
We envisaged that the aprotic environment should stabilizeform 69a, while the 
presence of water may promote the zwitterion form 69b. We proved this 
hypothesis through NMR titration (1D proton and carbon, see experimental 
section reported below) In this way for the first time, to the best of our 
knowledge, we demonstrated the presence of Berberrubine tautomerism.173 
Berberrubine 69 was prepared starting from Berberine 68 by pyrolysis in a 
solvent free conditions under vacuum175 (Scheme 8, route a) and microwave 
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irradiation176 (Scheme 8, route b). Differently from the microwave assisted 
synthetic procedure described by Das et al,176 which employed a commercial 
microwave oven, we performed the reaction taking advantage of scientific single 
mode microwave apparatus, that gave us the possibilities to set up reproducible 
conditions. 
 
SCHEME8a 
 
 
 
 
aReagents and conditions: (a) Berberine, 190-200° C, 30-40 mmHg, 15-20 min; (b) 
Berberine, MW, 250 W, 200°C, 10-15 min. 
 
Demethyleneberberine 71 was semi-synthesized through hydrolysis reaction of 
Berberine acetal ring, in the presence of sulfuric acid and phloroglucin175 
(Scheme 9). 
 
SCHEME 9a 
 
 
 
aReagents and conditions: a) Berberine, 60% H2SO4, phloroglucin. 
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Experimental Section 
 
General Synthetic Procedure and characterization of Berberrubine (69-
69a-69b) and Demethyleneberberine (71) 
 
Synthesis of Berberrubine quinoid form 69a (route a) 
Berberine chloride 68 (1 g, 2.7 mmol) was heated at 195°-200° C for 10-15 
min under vacuum (20-30 mmHg) to afford dark wine solid, which was washed 
with Et2O dry and filtered, to give compound 69a.  
69a: 0.7 g(yield 81%); red-purple powder, 1H NMR (400 MHz, DMSO-d6,) δ 
3.10 (t, 2H, J= 6.0 Hz), 3.79 (s, 3H), 4.54 (t, 2H, J= 6.0 Hz), 6.16 (s, 2H), 6.41 (d, 
1H, J= 8 Hz), 7.02 (s, 1H), 7.27 (d, 1H, J= 8 Hz), 7.67 (s, 1H), 8.04 (s, 1H), 9.14 
(s, 1H). 13C NMR (100 MHz, DMSO-d6,) δ 27.5, 52.3, 55.7, 100.6, 101.5, 104.7, 
108.2, 117.1, 120.0, 121.2, 121.8, 129.2, 132.0, 133.2, 145.7, 147.3, 148.3, 149.7, 
167.3.  
 
Synthesis of Berberrubine quinoid form 69a(route b) 
Berberine chloride 68 (0.1 g, 0.27 mmol) was taken in a vessel and the sample 
was irradiate at 250 W, 200°C for 10-15 min to afford dark wine solid, which was 
washed with Et2O dry and filtered, to give compound 69a. 
69a: 0.06 g(yield 70%); red-purple powder,1H NMR (400 MHz, DMSO-d6,) δ 
3.10 (t, 2H, J= 6.0 Hz), 3.79 (s, 3H), 4.54 (t, 2H, J= 6.0 Hz), 6.16 (s, 2H), 6.41 (d, 
1H, J= 8 Hz), 7.02 (s, 1H), 7.27 (d, 1H, J= 8 Hz), 7.67 (s, 1H), 8.04 (s, 1H), 9.14 
(s, 1H). 13C NMR (100 MHz, DMSO-d6,) δ 27.5, 52.3, 55.7, 100.6, 101.5, 104.7, 
108.2, 117.1, 120.0, 121.2, 121.8, 129.2, 132.0, 133.2, 145.7, 147.3, 148.3, 149.7, 
167.3. 
 
Preparation of Berberrubine enolic form 69 
The quinoid from 69a was treated with HCl 1N to obtain Berberrubine 69 like 
chloride salt. 
69: slightly yellow powder, 1H NMR (400 MHz, DMSO-d6,) δ 3.25 (t, 2H, J= 
6 Hz), 4.10 (s, 3H), 4.96 (t, 2H, J= 6 Hz), 6.23 (s, 2H), 7.12 (s, 1H), 7.76 (d, 1H, 
J= 8 Hz), 7.84 (s, 1H), 8.15 (d, 1H,  J= 8 Hz), 8.89 (s, 1H), 9.97 (s, 1H), 11.32 (br 
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s, 1H). 13C NMR (100 MHz, DMSO-d6) δ 26.5, 54.9, 57.1, 102.0, 105.4, 108.4, 
117.6, 118.1, 119.8, 120.7, 125.5, 130.5, 132.4, 136.6, 143.7, 145.4, 145.8, 147.7, 
149.6. 
 
Preparation of Demethyleneberberine 71 
To a stirred  solution of 60% H2SO4 (50 mL), phloroglucin (2.5 g, 20 mmol) 
was added portion wise to form a colorless solution. Berberine (BBR) (2.5 g, 6.5 
mmol) was added portion wise and the resulting system was stirred at 90-95°C for 
10-15 min. Then the mixture was poured into brine and the resulting mixture was 
stirred at room temperature for 2 h and cooled down to precipitate completely. 
The crude product was placed on a short pad of silica gel and eluted with CH2Cl2/ 
CH3OH to afford to the desired compound  
71: Demethyleneberberine (0.97 g, yield: 46%). 1H NMR (DMSO-d6, 400 
MHz) δ 3.08 (t, 2H, J= 6.0 Hz), 4.03 (s, 3H), 4.05 (s, 3H), 4.86 (t, 2H, J= 6.0 Hz), 
6.79 (s, 1H), 7.48 (s, 1H), 8.01 (d, 1H, J= 8.8 Hz), 8.13 (d, 1H, J= 9.2 Hz), 8.72 
(s, 1H), 9.29 (br s, 1H), 9.79 (s, 1H), 10.08 (br s, 1H). 13C NMR (DMSO-d6, 100 
MHz) δ 25.8, 52.9, 55.6, 57.1, 61.9, 112.7, 114.9, 117.8, 119.3, 121.2, 123.5, 
126.7, 127.2, 133.3, 138.3, 143.5, 145.1, 145.6, 149.2, 150.  
 
 
NMR studies of M1 forms (69,69a,69b) 
In the past years several spectroscopic studies concerning protoberberine alkaloids 
were performed (UV-VIS,172,177,178 NMR179,180). 
Some of these paper reported important information about Berberrubine. In most 
cases Berberrubine was represented as enol structure 69174,175,178,179 (Figure 39) 
with hydroxyl group in position C13, otherwise it was suggested either quinoid 
structure 69a171,176 (Figure 39) or zwitterionc form 69b171,172 (Figure 39), as 
result of tautomerization process.171  
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Figure 39. Three possible forms describing Berberrubine: enol 69, quinoid 69a or 
zwitterionic 69b forms. 
 
In this work our efforts were directed to investigate the interconversion 
between the three forms: 69, 69a and 69b. NMR analysis of the product 69a, 
exhibited a CO signal at 167.3 ppm, corresponding to C13 position, consistent 
with its quinoid structure 69a. By treatment of 69a with HCl, 69 was obtained and 
its structure was confirmed by 1H-NMR spectrum showing a broad signal at 11.32 
ppm corresponding to the –OH proton of C13. Resonance assignments and 
structures of both forms 69 and 69a were verified by 1D Proton and Carbon NMR 
spectra combined with 2D HSQC and HMBC178 (Figures 40-43).  
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Figure 40. 400 MHz HSQC NMR Spectrum of 69 in DMSO-d6. 
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Figure 41. 400 MHz HMBC NMR Spectrum of 69 in DMSO-d6. 
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Figure 42. 400 MHz HSQC NMR Spectrum of 69a in DMSO-d6. 
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Figure 43. 400 MHz HMBC NMR Spectrum of 69a in DMSO-d6. 
 
We propose the existence of keto-enol tautomerism between 69 and 69a, and 
quinoid-zwitterion resonance for 69a and 69b (Figure 39). In order to prove the 
equilibrium between 69 and 69a, we performed 1H-NMR analysis on a sample 
consistent of equimolar mixture of both forms. The spectrum displayed only one 
average set of signals demonstrating the existence of fast equilibration between 
this two tautomeric forms. To further validate the existence of a possible 
equilibrium between the tautomeric forms 69 and 69a, we carried out for both 
structures a 1H-15N HMQC (Figures 44-45) correlation analysis, recorded at 40° 
C in DMSO-d6.173 
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Figure 44. 600 MHz HMQC NMR Spectrum of 69 in DMSO-d6. 
 
 
Figure 45. 600 MHz HMQC NMR Spectrum of 69a in DMSO-d6. 
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Considering form 69, correlations (Figure 46, A) were observed from H8 
triplet and the H11 singlet to the N10 resonance at 193 ppm. Regarding structure 
69a, the same correlations (Figure 46, B) from H8 triplet and the H11 singlet to 
the N10 were obviously observed, but in this case the N10 resonance was found at 
164 ppm. Different chemical shifts for the two 15N resonances, are quite 
reasonable based on a different electron density due to the presence of quaternary 
N atom in 69 with respect to tertiary N atom in structure 69a. These data were 
consistent with the existence of these two tautomeric forms. 
 
 
                         A                                                                        B 
Figure 46. 1H-15N HMQC correlations for the enolic 69 and quinoid 69a forms of 
Berberrubine. 
 
Regarding the equilibrium involving quinoid 69a and zwitterionic 69b forms of 
Berberrubine (Figure 39), we suggested a quinoid-zwitterion resonance in 
agreement with Suau et al.174 that proposed an analogue betaine-quinoid 
resonance for the protoberberine alkaloid 7,8-dehydrocaseamine. We envisaged 
that the aprotic environment determined by the solvent DMSO-d6, used to collect 
NMR spectra, should stabilized form 69a, while the presence of water in this 
deuterate solvent may promote the zwitterion formation 69b. To gain more insight 
into the water’s effect, NMR titration (1D proton and carbon) was performed. 
Increasing amounts of water were added to a sample of 69 in DMSO-d6. NMR 
spectra recorded at increasing of water content showed shifted peaks assigned to 
the nuclei most involved in the structure rearrangement such as: H16, C16, C13 
124 
(Table 6). These chemical shift values δ were chosen as markers to follow the 
process (Figures 47-49).173  
 
Table 6. 1H and 13C NMR Data for Berberrubine (69, 69a, 69b) in DMSO-d6. 
 
Position Compound 
 69 69a 69b 
 δC δH (J in Hz) δC δH (J in Hz) δC δH (J in Hz) 
2 102.0 6.23, s 101.5 6.16, s 101.9 6.13, s 
4 149.6  148.3  148.8  
5 147.7  147.3  147.6  
6 108.4 7.12, s 108.2 7.02, s 108.6 7.00, s 
7 130.5  129.2  129.7  
8 26.5 3.25, t (6) 27.5 3.10, t (6) 27.7 3.11, t (6) 
9 54.9 4.96, t (6) 52.2 4.54, t (6) 53.2 4.54, t (6) 
11 145.8 9.97, s 145.7 9.14, s 146.3 9.14, s 
12 117.6  120.0  120.2  
13 143.7  167.3  166.1  
14 145.4  149.7  150.0  
15 125.5 8.15, d (8) 121.2 7.27, d (8) 122.0 7.35, d (8) 
16 118.1 7.76, d (8) 100.6 6.42, d (8) 102.9 6.67, d (8) 
17 132.4  132.0  132.3  
18 119.8 8.89, s 117.1 8.04, s 117.8 8.07, s 
19 136.6  133.2  133.7  
20 119.8  121.8  122.2  
21 105.4 7.83, s 104.7 7.67, s 105 7.62, s 
22 (-OH) 11.32, s br     
24 57.0 4.10, s 55.7 3.79, s 56.2 3.79, s 
 
  
Figure 47. The 13C chemical shifts of signal C13, (
DMSO-d6 as function of water content.
 
 
Figure 48. The 1H chemical shifts of signal H16, (
d6 as function of water content.
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69a), measured at 100 MHz in 
 
69a),measured at 400 MHz in DMSO
 
 
 
 
-
Figure 49. The 13C chemical shifts of signal C16,(
d6 as function of water content.
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69a),measured at 100 MHz in DMSO
 
 
 
-
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